
<html lang="en"     class="pb-page"  data-request-id="e574fdf1-99fc-4585-8f53-81607a177fb4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2012.55.issue-23;wgroup:string:ACHS website Group;article:article:10.1021/jm301365e;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations" /></meta><meta name="dc.Creator" content="Jiao  Yang" /></meta><meta name="dc.Creator" content="Li-Jiao  Wang" /></meta><meta name="dc.Creator" content="Jing-Jing  Liu" /></meta><meta name="dc.Creator" content="Lei  Zhong" /></meta><meta name="dc.Creator" content="Ren-Lin  Zheng" /></meta><meta name="dc.Creator" content="Yong  Xu" /></meta><meta name="dc.Creator" content="Pan  Ji" /></meta><meta name="dc.Creator" content="Chun-Hui  Zhang" /></meta><meta name="dc.Creator" content="Wen-Jing  Wang" /></meta><meta name="dc.Creator" content="Xing-Dong  Lin" /></meta><meta name="dc.Creator" content="Lin-Li  Li" /></meta><meta name="dc.Creator" content="Yu-Quan  Wei" /></meta><meta name="dc.Creator" content="Sheng-Yong  Yang" /></meta><meta name="dc.Description" content="This paper describe the structural optimization of a hit compound, N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine (1), which is a reversible kinase inhibitor targeting both E..." /></meta><meta name="Description" content="This paper describe the structural optimization of a hit compound, N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine (1), which is a reversible kinase inhibitor targeting both E..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 16, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301365e" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301365e" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301365e" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301365e" /></link>
        
    
    

<title>Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301365e" /></meta><meta property="og:title" content="Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0015.jpeg" /></meta><meta property="og:description" content="This paper describe the structural optimization of a hit compound, N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine (1), which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity. Structure–activity relationship studies led to the identification of 9-cyclopentyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine (9e) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively. Compound 9e was further assessed for potency and selectivity in enzymatic assays and in vivo anti-NSCLC studies. The results indicated that compound 9e is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome. In vivo, oral administration of compound 9e at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301365e"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301365e">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301365e&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301365e&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301365e&amp;href=/doi/10.1021/jm301365e" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10685-10699</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm301345v" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm301411g" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structural Optimization and Structure–Activity Relationships of <i>N</i><sup>2</sup>-(4-(4-Methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiao++Yang">Jiao Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li-Jiao++Wang">Li-Jiao Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing-Jing++Liu">Jing-Jing Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Zhong">Lei Zhong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ren-Lin++Zheng">Ren-Lin Zheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Xu">Yong Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pan++Ji">Pan Ji</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chun-Hui++Zhang">Chun-Hui Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wen-Jing++Wang">Wen-Jing Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xing-Dong++Lin">Xing-Dong Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lin-Li++Li">Lin-Li Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu-Quan++Wei">Yu-Quan Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheng-Yong++Yang">Sheng-Yong Yang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">West China School of Pharmacy, Sichuan University, Sichuan 610041, China</span></div><div class="corresp-info"><strong>*</strong>Phone: +86-28-85164063. Fax: +86-28-85164060. E-mail: <a href="/cdn-cgi/l/email-protection#90e9f1fef7e3e9d0e3f3e5bef5f4e5bef3fe"><span class="__cf_email__" data-cfemail="a3dac2cdc4d0dae3d0c0d68dc6c7d68dc0cd">[email protected]</span></a>;.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301365e&amp;href=/doi/10.1021%2Fjm301365e" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10685–10699</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 1, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 September 2012</li><li><span class="item_label"><b>Published</b> online</span>16 November 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 December 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301365e" title="DOI URL">https://doi.org/10.1021/jm301365e</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10685%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJiao%2BYang%252C%2BLi-Jiao%2BWang%252C%2BJing-Jing%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D23%26contentID%3Djm301365e%26title%3DStructural%2BOptimization%2Band%2BStructure%25E2%2580%2593Activity%2BRelationships%2Bof%2BN2-%25284-%25284-Methylpiperazin-1-yl%2529phenyl%2529-N8-phenyl-9H-purine-2%252C8-diamine%2BDerivatives%252C%2Ba%2BNew%2BClass%2Bof%2BReversible%2BKinase%2BInhibitors%2BTargeting%2Bboth%2BEGFR-Activating%2Band%2BResistance%2BMutations%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10699%26publicationDate%3DDecember%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301365e"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4065</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">32</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301365e" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jiao&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Li-Jiao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jing-Jing&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Zhong&quot;},{&quot;first_name&quot;:&quot;Ren-Lin&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Pan&quot;,&quot;last_name&quot;:&quot;Ji&quot;},{&quot;first_name&quot;:&quot;Chun-Hui&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Wen-Jing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xing-Dong&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Lin-Li&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yu-Quan&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Sheng-Yong&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;10685-10699&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301365e&quot;},&quot;abstract&quot;:&quot;This paper describe the structural optimization of a hit compound, N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine (1), which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity. Structure–activity relationship studies led to the identification of 9-cyclopentyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine (9e) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively. Compound 9e was further assessed for potency and selectivity in enzymatic assays and in vivo anti-NSCLC studies. The results indicated that compound 9e is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome. In vivo, oral administration of compound 9e at a dose of 5 mg/kg caused rapid an&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301365e&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301365e" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301365e&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301365e" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301365e&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301365e" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301365e&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301365e&amp;href=/doi/10.1021/jm301365e" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301365e" /></input><a href="/doi/pdf/10.1021/jm301365e" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301365e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301365e%26sid%3Dliteratum%253Aachs%26pmid%3D23116168%26genre%3Darticle%26aulast%3DYang%26date%3D2012%26atitle%3DStructural%2BOptimization%2Band%2BStructure%25E2%2580%2593Activity%2BRelationships%2Bof%2BN2-%25284-%25284-Methylpiperazin-1-yl%2529phenyl%2529-N8-phenyl-9H-purine-2%252C8-diamine%2BDerivatives%252C%2Ba%2BNew%2BClass%2Bof%2BReversible%2BKinase%2BInhibitors%2BTargeting%2Bboth%2BEGFR-Activating%2Band%2BResistance%2BMutations%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D23%26spage%3D10685%26epage%3D10699%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jmcmar.2012.55.issue-23/production/jmcmar.2012.55.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">This paper describe the structural optimization of a hit compound, <i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>1</b>), which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity. Structure–activity relationship studies led to the identification of 9-cyclopentyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>9e</b>) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively. Compound <b>9e</b> was further assessed for potency and selectivity in enzymatic assays and in vivo anti-NSCLC studies. The results indicated that compound <b>9e</b> is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome. In vivo, oral administration of compound <b>9e</b> at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11363" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11363" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lung cancer has become the leading cause of cancer-related deaths worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> More than 80% of all lung cancers are identified as non-small-cell lung cancer (NSCLC). The epidermal growth factor receptor (EGFR) has been established as one of the most important therapeutic targets for NSCLC.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Two small-molecule inhibitors of EGFR, gefitinib and erlotinib, have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of NSCLC.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a> Both drugs can be classified as first-generation reversible, ATP-competitive inhibitors. Clinical studies indicate that NSCLC patients with EGFR-activating mutations, namely, exon 19 deletion or L858R mutations, benefit most from gefitinib/erlotinib treatment.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7-9)</a> Unfortunately, NSCLCs with EGFR-activating mutations eventually develop resistance to these drugs, and in approximately half of these cases, resistance is caused by a single secondary mutation in the EGFR exon 20, resulting in a Thr-to-Met substitution at residue 790 (T790M).<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> A recent study by Yun and Eck indicated that the introduction of the T790 M mutation greatly increases the ATP binding affinity of the oncogenic activating mutant, hence reducing the potency of ATP-competitive kinase inhibitors.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Their study suggested that simply removing some of the steric hindrance from the current drugs is insufficient to restore potency to the T790 M mutant. To overcome the enhanced ATP binding in T790 M mutants, the next-generation drug must bind to the T790 M mutant with higher affinity than that of the first-generation drugs. Irreversible EGFR inhibitors containing a Michael acceptor functional group have been developed to overcome this enhanced ATP binding by irreversibly alkylating a cysteine residue (C797) in the ATP binding site of the EGFR.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21">(14-21)</a> However, except for a few examples, such as BIBW2992,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> PF00299804,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and WZ-4002,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> these irreversible inhibitors have thus far shown limited clinical efficacy. Inherent weaknesses, including relatively high toxicity and a decreased binding velocity to the mutant kinase, may be responsible for the lack of clinical efficacy.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24-26)</a> Hence, the development of next-generation reversible EGFR inhibitors that can inhibit the drug-resistant T790M-bearing mutants and remain potent in other activating mutants is a highly attractive goal that has received much attention in recent years.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30">(27-30)</a></div><div class="NLM_p">In an effort to discover inhibitors with novel scaffolds that are more potent against both EGFR-activating and resistance mutations, we performed a virtual screening against an in-house focused library containing approximately 650 000 known kinase inhibitors and kinase inhibitor-like compounds containing common kinase inhibitor core scaffolds (for details, see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). The virtual screen was followed by kinase inhibitory assays, which allowed us to find a hit compound, <i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A). This compound exhibits an ability to inhibit both EGFR-activating and resistance mutations; the IC<sub>50</sub> values for the EGFR L858R and L858R/T790 M mutations are 0.098 and 0.978 μM, respectively. In cellular assays, compound <b>1</b> displayed inhibitory activity against the gefitinib-sensitive NSCLC cell line HCC827 that bears the exon 19 deletion EGFR mutation (Del E746_A750, IC<sub>50</sub> = 0.233 μM), but exhibited a weak inhibitory potency against the gefitinib-resistant NSCLC cell line H1975 that harbors the L858R/T790 M EGFR mutation (IC<sub>50</sub> = 18.06 μM). Although compound <b>1</b> has some ability to inhibit both EGFR-activating and resistance mutations, the potencies are insufficient. In particular, the relatively poor potency against the T790 M EGFR mutation indicates that it cannot overcome the enhanced ATP binding found in T790 M EGFR. Our goal in this study was to optimize the structure of compound <b>1</b> and derive compounds with higher potency that can inhibit the drug-resistant T790M-bearing mutants while remaining potent in the presence of the activating mutations. A series of novel 2,8-dianilinopurine derivatives were synthesized and tested for bioactivity. The most potent derivative, compound <b>9e</b>, was then subjected to further evaluation of its antitumor activities both in vitro and in vivo. We report the chemical synthesis and structure–activity relationships (SARs) between this novel series of compounds and the in vitro and in vivo anti-NSCLC activities of compound <b>9e</b>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Structure of hit compound <b>1</b>. (B) Moieties in compound <b>1</b> targeted for modification in this study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">2.1 Synthesis of 2,8-Dianilinopurine Derivatives</h3><div class="NLM_p">Structural optimization was carried out by focusing on the N-9 (H), C-2 (anilino group), and C-8 positions (anilino group) of the purine scaffold (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>B). Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> depicts the synthetic route to the 2,8-dianilinopurine derivatives <b>9a</b>–<b>h</b> in which the N-9 (H) position of the purine scaffold is substituted by various groups. Commercially available 4-fluoronitrobenzene (<b>2</b>) reacted with 1-methylpiperazine in the presence of K<sub>2</sub>CO<sub>3</sub> in DMSO to produce the intermediate <b>3</b>. The catalytic hydrogenation of the nitro functionality in <b>3</b> with palladium on carbon (Pd/C) provided the desired aniline <b>4</b> in excellent yield. Reaction of the commercially available 2,4-dichloro-5-nitropyrimidine (<b>5</b>) with various amines, including ammonia, methanamine, cyclopropanamine, propan-2-amine, cyclopentylamine, cyclohexylamine, aniline, and 3,5-dimethylaniline, produced intermediates <b>6a</b>–<b>h</b>. Nucleophilic aromatic substitution of the 2-chloro position in <b>6a</b>–<b>h</b> with <b>4</b> in <i>n</i>-butanol at 90 °C yielded compounds <b>7a</b>–<b>h</b>. Subsequent hydrogenation of the nitro group in <b>7a</b>–<b>h</b> using Pd/C as a catalyst provided a good yield of the desired intermediates <b>8a</b>–<b>h</b>, which were treated with isothiocyanatobenzene to produce the final 2,8-dianilinopurine derivatives <b>9a</b>–<b>h</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 2,8-Dianilinopurine Derivatives <b>9a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) 1-methylpiperazine, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 6 h, 95%; (ii) H<sub>2</sub>, 10% Pd/C, EtOH, rt, 9 h, 90%; (iii) CH<sub>2</sub>Cl<sub>2</sub>, DIEA, amine, −60 °C to room temperature, 60–75%; (iv) <i>n</i>-butanol, 90 °C, 5 h, 76%; (v) H<sub>2</sub>, 10% Pd/C, MeOH, 50 °C, 6 h, 85%; (vi) CH<sub>2</sub>Cl<sub>2</sub>, DIEA, EDIC, isothiocyanatobenzene, reflux, 12 h, 35–60%.</p></p></figure><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> shows a general route for the synthesis of 2,8-dianilino-9-cyclopentylpurine derivatives <b>14a</b>–<b>e</b> bearing different substituents on the phenyl ring of the 2-anilino group. The fluorine in 4-fluoronitrobenzene was substituted via conventional nucleophilic aromatic substitution using morpholine, 4-methylpiperidine, and ethanolamine in the presence of K<sub>2</sub>CO<sub>3</sub> in DMSO to yield the corresponding substituted nitrobenzenes <b>10a</b>, <b>10b</b>, and <b>10c</b>, respectively. As before, the nitro functional groups in compounds <b>10a</b>–<b>c</b> were reduced via catalytic hydrogenation to generate the corresponding anilines <b>11a</b>–<b>c</b> in high yield. These intermediates, <b>11a–c</b>, along with the commercially available compounds <b>11d</b> and <b>11e</b> were treated with compound <b>6e</b> in <i>n</i>-butanol at 90 °C to produce <b>12a</b>–<b>e</b>. These compounds were then hydrogenated with catalytic Pd/C, and the resultant intermediates (<b>13a</b>–<b>e</b>) were treated with isothiocyanatobenzene to yield the final 2,8-dianilino-9-cyclopentylpurine derivatives <b>14a</b>–<b>e</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 2,8-Dianilino-9-cyclopentylpurine Derivatives <b>14a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) morpholine, 4-methylpiperidine, ethanolamine, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 6 h, 70–85%; (ii) H<sub>2</sub>, 10% Pd/C, EtOH, rt, 9 h, 90%; (iii) <i>n</i>-butanol, 90 °C, 5 h, 76%; (iv) H<sub>2</sub>, 10% Pd/C, MeOH, 50 °C, 6 h, 85%; (v) CH<sub>2</sub>Cl<sub>2</sub>, DIEA, EDIC, isothiocyanatobenzene, reflux, 12 h, 35–60%.</p></p></figure><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a> depicts the synthetic route to 2,8-dianilino-9-cyclopentylpurine derivatives <b>18a</b>–<b>j</b> with different substituents on the phenyl ring of the 8-anilino group. Substituted anilines <b>15a</b>–<b>j</b> reacted with CS<sub>2</sub> and DABCO in ethanol at room temperature to yield the intermediate compounds <b>16a</b>–<b>j</b>, which were directly treated with triphosgene at 35–40 °C in dichloromethane to produce substituted phenyl isothiocyanates <b>17a</b>–<b>j</b> with yields of 45–60%. Compounds <b>17a</b>–<b>j</b> were treated with compound <b>8e</b> and EDCI in the presence of <i>N</i>,<i>N</i>-diisopropylamine in dichloromethane to yield the final 2,8-dianilino-9-cyclopentylpurine derivatives <b>18a</b>–<b>j</b> in acceptable yields.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 2,8-Dianilino-9-cyclopentylpurine Derivatives <b>18a</b>–<b>j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) EtOH, CS<sub>2</sub>, DABCO, rt, 12 h, 60%; (ii) CH<sub>2</sub>Cl<sub>2</sub>, triphosgene, 0 °C, 1 h, reflux, 4 h, 65%; (iii) CH<sub>2</sub>Cl<sub>2</sub>, DIEA, EDIC, reflux, 12 h, 35–60%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.2 SAR of 2,8-Dianilinopurine Derivatives</h3><div class="NLM_p">Cell-based assays were used to evaluate the bioactivity of the synthesized compounds in the SAR studies. Two human NSCLC cell lines, HCC827 and H1975, and a human hepatocellular carcinoma cell line, HepG2, were used in the study. These cell lines were selected for several reasons: The HCC827 cell line harbors an EGFR-activating mutation (deletion mutation) and is a representative EGFR-driven cell line. The H1975 cell line bears the drug resistance mutation in EGFR (L858R/T790M) and is a typical EGFR-driven cell line. Clearly, these two cell lines are suitable for studies seeking inhibitors of EGFR-activating and resistant mutants. The use of HepG2, which harbors wild-type EGFR and is not dependent on EGFR signaling for cell growth, is used to rule out activity due to non-EGFR-mediated effects (“off target” or cellular toxicity effects). The SAR obtained from such cell-based assays potentially reports a combination of the intrinsic activity of the compounds against the kinase target and the ability of the compounds to permeate the cell membrane during the assay. The enzymatic binding affinities of the inhibitors with the highest potency at the cellular level were also measured. The most potent compound in both the enzymatic and cellular assays was selected for in vivo experiments to evaluate its activity against NSCLC. Another advantage of using cell-based assays in the SAR studies is their reduced cost relative to enzymatic assays, which is especially meaningful in an academic setting.</div><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">2.2.1 Substitution Effects at the N-9 Position of the Purine</h4><div class="NLM_p">To explore the effect of substitution at the N-9 position of the purine scaffold, we synthesized compounds <b>9a</b>–<b>h</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>), which contain hydrophobic substituents of different sizes at the N-9 purine position. The antiviability activities of compounds <b>9a</b>–<b>h</b> against the HCC827, H1975, and HepG2 cell lines are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Introduction of a methyl group (<b>9b</b>) at the N-9 position of the purine increases its antiviability activity against both H1975 and HCC827. Substitution with bulkier cyclopropyl (<b>9c</b>) and isopropyl (<b>9d</b>) groups, which both contain three carbon atoms, further increases the antiviability activity against both the H1975 and HCC827 cells lines. Increasing the substituent size to cyclopentyl yields compound <b>9e</b>, which has an inhibitory potency (IC<sub>50</sub>) of 0.36 μM against H1975 and <0.00001 μM against HCC827. However, further increases in the substituent size (e.g., cyclohexyl (<b>9f</b>), phenyl (<b>9g</b>), or 3,5-dimethylbenzene (<b>9h</b>)) do not cause an increase in the bioactivity. On the contrary, these larger substituents lead to decreased bioactivity relative to cyclopentyl (<b>9e</b>), implying that cyclopentyl represents the optimum substituent size at the N-9 position. Additionally, most of these compounds have IC<sub>50</sub> values of >5 μM against the HepG2 cell line, indicating that the antiviability activity of compound <b>9e</b> against the HCC827 and H1975 cell lines is not due to cellular toxicity (the same situation will be seen below).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. 2,8-Dianilinopurine Derivatives Containing Different Substituents at the N-9 Position of the Purine Scaffold and Their Antiviability Activities against HCC827, H1975, and HepG2 Cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean  ± SD.</p></div></div><div></div></div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">2.2.2 Substitution on the Phenyl Ring of the 2-Anilino Group</h4><div class="NLM_p">We investigated the possible influence that substituents on the benzene ring of the 2-anilino group have on bioactivity. For this purpose, the N-9 cyclopentyl group and the C-8 anilino group were held constant. The leading derivatives, <b>14a</b>–<b>e</b> and <b>9e</b>, are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> with the corresponding bioactivity data. The different substituents on the benzene ring of the 2-anilino group have considerable influence on the antiviability activity against both H1975 and HCC827. However, compound <b>9e</b> remains the most active compound. Compound <b>9e</b> possesses a 4-methylpiperazine substituent, which is the most polar group explored at that position.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Compounds <b>9e</b> and <b>14a</b>–<b>c</b> Containing Different Substituents on the Benzene Ring of the 2-Anilino Group of the Purine Scaffold and Their Antiviability Activity against HCC827, H1975, and HepG2 Cells<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">2.2.3 Substitution on the Phenyl Ring of the 8-Anilino Group</h4><div class="NLM_p">We also examined the impact on bioactivity of the substitution onto the phenyl ring of the 8-anilino group. The N-2 and C-9 positions were held constant as 1-methyl-4-phenylpiperazine and cyclopentyl moieties, respectively. Substitution was introduced at the meta-, ortho-, and/or para-positions of the phenyl ring of the 8-anilino group. The best performing compounds, <b>18a</b>–<b>j</b> and <b>9e</b>, and their antiviability activity against the H1975, HCC827 and HepG2 cell lines are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Substitution of the 8-anilino group onto the phenyl ring reduced the antiviability activity against the HCC827 and H1975 cell lines, although the bioactivity against the HCC827 cell line was maintained at a picomolar level for most of the derivatives.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Compound <b>9e</b> and 2,8-Dianilino-9-cyclopentylpurine Derivatives <b>18a</b>–<b>j</b> Containing Substituents on the Phenyl Ring of the 8-Anilino Group and Their Antiviability Activity against HCC827, H1975, and HepG2 Cells<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">2.3 Rationalization of the Observed SAR Using Molecular Docking</h3><div class="NLM_p">The observed SAR demonstrates that a substituent of suitable size at the N-9 position of the purine scaffold can increase the binding affinity. Substitutions of the 2-anilino and 8-anilino groups onto the phenyl ring did not increase the bioactivity. To rationalize the observed SAR, molecular docking studies were performed. The binding mode of compound <b>1</b> within the active site of the T790 M EGFR mutant predicted by molecular docking is shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. The purine ring is located in the ATP-binding pocket and is sandwiched between the N- and C-lobes of the kinase. The molecule is oriented such that the 2-aniline branch extends toward the solvent and the 8-aniline moiety is directed into the back of the ATP-binding pocket. Two highly conserved hydrogen bonds are formed between compound <b>1</b> and the “hinge” region that links the N- and C-lobes of the kinase. The binding mode of compound <b>1</b> also reveals that a hydrophobic region near the N-9 position of the purine, which is normally occupied by the ribose moiety of ATP, remains unoccupied. A hydrophobic substituent on the N-9 position of the purine should be preferred and is expected to increase the binding affinity. This prediction is consistent with the previously observed SAR; substitutions at the N-9 position of the purine considerably increased the bioactivity. However, a substituent that is too large may become unfavorable given the limited size of the hydrophobic pocket. This prediction is also consistent with our observations that larger substituents (e.g., cyclohexyl, phenyl, and 3,5-dimethylphenyl) led to a decrease in the potency in comparison with the cyclopentyl group. In contrast, the 2-aniline branch of this molecule extends toward the solvent, and the polar 1-methylpiperazine group seems favorable at this position. The 8-anilino group is located in the back of ATP-binding pocket. Substitution on the phenyl ring of 8-aniline is not preferred, which is consistent with possible collisions between the substituent and the residues in the back of ATP-binding pocket.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Putative binding mode of compound <b>1</b> within the active pocket of the EGFR T790 M mutant (the EGFR T790 M structure was taken from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Hydrogen bonds are shown as black dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.4 Binding Affinities of Compound 9e to Various EGFR Mutations</h3><div class="NLM_p">The structural optimization and SAR studies beginning with compound <b>1</b> resulted in the discovery of compound <b>9e</b>, which is the most active compound of the analogues tested. The potency and selectivity of compound <b>9e</b> were further examined through enzymatic assays.</div><div class="NLM_p">The binding affinities (<i>K</i><sub>d</sub> values) of compound <b>9e</b> to various EGFR mutations including activating and drug-resistance mutations were measured using KINOME<i>scan</i> kinase binding assays (Ambit Biosciences), and the results are presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Compound <b>9e</b> has a picomolar binding affinity with wild-type (WT) EGFR (0.0006 μM) and various EGFR-activating mutations, including EGFR (E746-A750del) (IC<sub>50</sub> = 0.0005 μM), EGFR (L747-E749del, A750P) (IC<sub>50</sub> = 0.0004 μM), EGFR (L747-S752del, Sins) (IC<sub>50</sub> = 0.0005 μM), EGFR (L858R) (IC<sub>50</sub> = 0.0006 μM), EGFR (G719C) (IC<sub>50</sub> = 0.0007 μM), EGFR (G719S) (IC<sub>50</sub> = 0.0005 μM), and EGFR (L861Q) (IC<sub>50</sub> = 0.0006 μM). It also exhibited picomolar binding affinity to the drug-resistant T790 M EGFR mutant (L858R, T790M) (IC<sub>50</sub> = 0.0016 μM).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Binding Affinities of Compound <b>9e</b> to Various EGFR Mutations</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>d</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR (WT)</td><td class="colsep0 rowsep0" align="char" char=".">0.0006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR (E746-A750del)</td><td class="colsep0 rowsep0" align="char" char=".">0.0005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR (747-E749del, A750P)</td><td class="colsep0 rowsep0" align="char" char=".">0.0004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR (L747-S752del, Sins)</td><td class="colsep0 rowsep0" align="char" char=".">0.0005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR (L858R)</td><td class="colsep0 rowsep0" align="char" char=".">0.0006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR (G719C)</td><td class="colsep0 rowsep0" align="char" char=".">0.0007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR (G719S)</td><td class="colsep0 rowsep0" align="char" char=".">0.0005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR (L861Q)</td><td class="colsep0 rowsep0" align="char" char=".">0.0006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR (L858R, T790M)</td><td class="colsep0 rowsep0" align="char" char=".">0.0016</td></tr></tbody></table></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">2.5 Kinase Inhibition Profile for Compound 9e against Recombinant Human Protein Kinases</h3><div class="NLM_p">The kinase inhibition profile for compound <b>9e</b> against a panel of recombinant human protein kinases was measured using the “gold standard” radiometric kinase assay, and the results are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Compound <b>9e</b> was a potent inhibitor of EGFR(WT) with an IC<sub>50</sub> value of 0.004 μM. It also inhibited several other oncokinases including ERBB2, ERBB4, KIT, SRC, SYK, and p38α with moderate potencies (IC<sub>50</sub> = 0.06, 0.03, 0.54, 0.29, 0.72, and 0.23 μM, respectively), but only weakly inhibited ALK, MET, JAK1, JAK2, JAK3, JNK2, MNK1, MNK2, PKA, PKCα, PKCθ, PKN1, S6K, and TYK2 (IC<sub>50</sub> = 2.3, 6.4, 3.3, 1.2, 2.6, 1.5, 6.7, 3.2, 1.1, 6.7, 3.6, 6.1, 9.4, and 6.7 μM, respectively). Compound <b>9e</b> displayed almost no inhibitory activity in 20 other protein kinases. These data demonstrate that compound <b>9e</b> is a potent EGFR inhibitor with good kinase spectrum selectivity, although it also exhibits considerable potency against several other oncokinases.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinase Inhibition Profile for Compound <b>9e</b> against Human EGFR and a Panel of Other Selected Protein Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">JNK2</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">MK2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">MK5</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERBB2</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">MNK1</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERBB4</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">MNK2</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF1R</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">PDK1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">INSR</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">PIM2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KIT</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">PKA</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">PKBa</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MST1R</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">PKCα</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="char" char=".">0.29</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">PKCθ</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SYK</td><td class="colsep0 rowsep0" align="char" char=".">0.72</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">PKN1</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CK1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">PKN2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">COT1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">PLK1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CaMK2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">ROCK2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">S6K</td><td class="colsep0 rowsep0" align="char" char=".">9.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK3β</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">TYK2</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRAK4</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">VEGFR2</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">WNK1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">p38α</td><td class="colsep0 rowsep0" align="char" char=".">0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">p38γ</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr></tbody></table></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">2.6 In Vitro Antiviability Activity of Compound 9e</h3><div class="NLM_p">The antiviability potency of compound <b>9e</b> against various tumor cell lines was measured using the MTT assay method (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Compound <b>9e</b> displayed exceptional potency against NSCLC cell lines HCC827 and PC-9 (del E746_A750) with IC<sub>50</sub> values of <0.00001 and 0.00022 μM, respectively, and was much more potent than gefitinib (0.0015 and 0.014 μM, respectively; see Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). In the drug-resistant NSCLC cell line H1975, compound <b>9e</b> also exhibited good inhibition potency with an IC<sub>50</sub> value of 0.36 μM. In cell lines in which EGFR is overexpressed, including Calu-3, H292, A431, and FaDu, compound <b>9e</b> displayed higher inhibition potency than gefitinib. In other cell lines, including MDA-MB-231, HCT116, and HepG2, which bear a lower EGFR expression or present cell growth that is not dependent on EGFR, compound <b>9e</b> exhibited little or no inhibition potency. These results demonstrate the good cellular selectivity of compound <b>9e</b>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Antiviability Activities of Compound <b>9e</b> and Gefitinib against Various Cancer Cell Lines (IC<sub>50</sub>, μM)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cancer type</th><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">characteristic</th><th class="colsep0 rowsep0" align="center" char=".">compound <b>9e</b></th><th class="colsep0 rowsep0" align="center" char=".">gefitinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">HCC827</td><td class="colsep0 rowsep0" align="left">Del E746_A750 (EGFR mutant)</td><td class="colsep0 rowsep0" align="char" char="."><0.00001</td><td class="colsep0 rowsep0" align="char" char=".">0.0015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">PC-9</td><td class="colsep0 rowsep0" align="left">Del E746_A750 (EGFR mutant)</td><td class="colsep0 rowsep0" align="char" char=".">0.00022</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">H1975</td><td class="colsep0 rowsep0" align="left">L858R/T790 M (EGFR mutant)</td><td class="colsep0 rowsep0" align="char" char=".">0.36</td><td class="colsep0 rowsep0" align="char" char=".">∼10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">Calu-3</td><td class="colsep0 rowsep0" align="left">ErbB2 overexpressed</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">H292</td><td class="colsep0 rowsep0" align="left">EGFR overexpressed</td><td class="colsep0 rowsep0" align="char" char=".">0.045</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">epidermal</td><td class="colsep0 rowsep0" align="left">A431</td><td class="colsep0 rowsep0" align="left">EGFR overexpressed</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hypopharyngeal</td><td class="colsep0 rowsep0" align="left">Fadu</td><td class="colsep0 rowsep0" align="left">EGFR overexpressed</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast</td><td class="colsep0 rowsep0" align="left">MDA-MB-231</td><td class="colsep0 rowsep0" align="left">KRAS mutation (G13D)</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colon</td><td class="colsep0 rowsep0" align="left">HCT116</td><td class="colsep0 rowsep0" align="left">KRAS and PI3k mutations</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">HepG2</td><td class="colsep0 rowsep0" align="left">EGFR independent</td><td class="colsep0 rowsep0" align="char" char=".">>5</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr></tbody></table></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">2.7 Inhibition of EGFR Autophosphorylation and the Inactivation of Downstream Signaling Proteins in Cell Cultures</h3><div class="NLM_p">The ability of compound <b>9e</b> to inhibit the activation of EGFR and the downstream signaling proteins with which it interacts were assessed using Western blot analysis, and the results are presented in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. In the HCC827 cell line, compound <b>9e</b> inhibited EGFR phosphorylation at a low concentration (<0.00001 μM) and down-regulated the phosphorylation of the downstream signaling proteins, AKT and the extracellular signal-regulated kinase (ERK). This effect was more pronounced with compound <b>9e</b> than with gefitinib. In the EGF-stimulated H1975 cell line, compound <b>9e</b> inhibited EGF-dependent phosphorylation of EGFR and the downstream signaling proteins AKT and ERK in a dose-dependent manner with an estimated IC<sub>50</sub> value of 0.4 μM. However, the EGFR signaling pathway was not inhibited by gefitinib at a concentration of 10 μM.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of EGFR autophosphorylation and inactivation of downstream signaling proteins in cell cultures by compound <b>9e</b>. (A) HCC827 cells were treated with compound <b>9e</b> or gefitinib for 8 h. The cells were lysed, and the proteins were assessed by Western blot assay. (B) Serum-starved H1975 cells were treated with compound <b>9e</b> or gefitinib for 3 h, followed by the addition of EGF (100 ng/mL) for 15 min. Protein extracts were then analyzed by Western blot assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">2.8 In Vivo Anti-NSCLC Effects of Compound 9e</h3><div class="NLM_p">The in vivo anti-NSCLC effects of compound <b>9e</b> were evaluated using HCC827 and H1975 tumor xenograft models. In the HCC827 tumor model, the mice were treated via oral gavage once daily with either compound <b>9e</b> or gefitinib once the tumor had grown to a volume of 300–500 mm<sup>3</sup>. At all doses tested, compound <b>9e</b> markedly inhibited the tumor growth, and a 5 mg/kg/day dose of compound <b>9e</b> resulted in complete tumor regression within 15 days of treatment (see Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A). Similar results were observed with gefitinib at a dose of 100 mg/kg/day. Moreover, at the dose of 1 mg/kg/day, compound <b>9e</b> displayed better antitumor activity than gefitinib.</div><div class="NLM_p">In the H1975 tumor model, established sc tumors with volumes of 50–100 mm<sup>3</sup> were treated with compound <b>9e</b>. Oral administrations of the compound at 25 and 50 mg/kg/day inhibited tumor growth in a dose-dependent manner at rates of 35 and 62%, respectively (see Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B). Treatment with gefitinib at 100 mg/kg produced only a marginal effect on tumor growth (23% inhibition, data not shown). BIBW2992 (an irreversible EGFR inhibitor) was used as a positive control and had an inhibition rate of 74% at a dose of 20 mg/kg/day. During the experiment, only minor weight loss was observed in the high-dose groups (compound <b>9e</b>, 4.4% at 50 mg/kg; BIBW2992, 6.6% at 20 mg/kg), which was recovered with continued treatment.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo antitumor effects of compound <b>9e</b> and its action mechanism. (A) Tumor growth curves for the HCC827 xenograft model. (B) Tumor growth curves for the H1975 xenograft model. Animals were randomized into groups (<i>n</i> = 6–8/group) and administered compound <b>9e</b>, gefitinib, BIBW2992, or vehicle once daily at the indicated dose levels when tumors reached the determined size. In both models, the animal weight and tumor volume were monitored twice weekly. Points indicate mean tumor volume (mm<sup>3</sup>); bars indicate SD. (C, D) Histological and immunohistochemical analyses demonstrating the effects of compound <b>9e</b> on the inhibition of EGFR phosphorylation and cell proliferation (Ki67) in tumor tissues. (C) In the HCC827 model, a dose of 1 mg/kg/day of compound <b>9e</b> was administered. After treatment for 3 days, the tumors were collected and analyzed. (D) In the H1975 model, a dose of 50 mg/kg/day was administered, and the tumors were collected and analyzed after 10 days of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The ability of compound <b>9e</b> to inhibit EGFR phosphorylation and cell proliferation (Ki67) in tumor tissues was also evaluated using histological and immunohistochemical techniques (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>C,D). In the HCC827 model, a 1 mg/kg/day dose of compound <b>9e</b> was administered, and after treatment for 3 days, the tumors were collected and analyzed. In the H1975 model, a dose of 50 mg/kg/day was administered, and tumors were collected and analyzed after 10 days of treatment. In both models, significant decreases were observed in the staining of EGFR phosphorylation and Ki67 for those groups treated with compound <b>9e</b> as compared with the control groups. These findings indicate that compound <b>9e</b> significantly inhibited the EGFR phosphorylation and reduced the proliferation ability of the tumor cells.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">2.9 Pharmacokinetic Characteristics of Compound 9e</h3><div class="NLM_p">The pharmacokinetic parameters of compound <b>9e</b> following per os administration in male rats are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>. After oral administration at a single dose of 20 mg/kg, compound <b>9e</b> displayed a CL of 9.72 L/h/kg with a moderate <i>t</i><sub>1/2</sub> of 4.86 h. The steady-state volume (<i>V+</i><sub>ss</sub> = 63.35 L/kg) was much larger than the volume of total body water, suggesting extravascular distribution. Moreover, the absorption of compound <b>9e</b> was relatively quick and reached a maximum plasma concentration (<i>C</i><sub>max</sub> = 0.23 mg/L) in 1–3 h.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Parameters for Compound <b>9e</b> in Plasma after the Oral Administration of a 20 mg/kg Dose to Sprague–Dawley Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">po (20 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0–24h)</sub>(mg/L × h)</td><td class="colsep0 rowsep0" align="left">2.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">4.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">1–3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">63.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L/h/kg)</td><td class="colsep0 rowsep0" align="left">9.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (mg/L)</td><td class="colsep0 rowsep0" align="left">0.23</td></tr></tbody></table></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">3 Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48574" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48574" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described the structural optimization of a hit compound, <i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>1</b>), which exhibited poor binding affinity (<i>K</i><sub>d</sub>) for both EGFR-activating and drug-resistant mutants. SAR studies centering around the N-9 (H), C-2 (anilino), and C-8 (anilino) groups of the purine scaffold led to the discovery of compound <b>9e</b>. This compound exhibited significantly increased antiviability potency against the HCC827 cell line, which harbors an activating mutation in EGFR, and the H1975 cell line, which contains the drug-resistance EGFR mutation T790M. Compound <b>9e</b> displayed only weak inhibition against HepG2, a cell line that is not EGFR-driven. Further in vitro assays indicated that compound <b>9e</b> has a high potency against both EGFR-activating and drug-resistant EGFR mutants and good kinase spectrum selectivity, while also inhibiting several other oncokinases. Western blot analysis showed that compound <b>9e</b> significantly inhibited EGFR phosphorylation and the activation of downstream signaling proteins. In vivo antitumor activity assays showed that an oral, once-daily dose of compound <b>9e</b> at 5 mg/kg for 15 days led to complete tumor regression in the HCC827 xenograft model and that a once-daily dose of compound <b>9e</b> at 50 mg/kg exhibited considerable tumor inhibition in the H1975 xenograft model. Preliminary pharmacokinetic studies indicated that compound <b>9e</b> possesses good pharmacokinetic properties. Because compound <b>9e</b> is a multikinase inhibitor, synergistic effects from the simultaneous inhibition of EGFR and other kinases are possible. Further detailed studies of the action mechanisms of compound <b>9e</b> are underway and will be reported elsewhere.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">4 Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chemistry Methods</h3><div class="NLM_p">Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. The syntheses of compounds <b>9a</b>–<b>g</b>, <b>14a</b>–<b>e</b>, and <b>18a</b>–<b>j</b> were as previously reported. The purity of all final compounds was determined by high-performance liquid chromatography (HPLC) analysis to be >95%. HPLC analysis was carried out on a Waters 2695 HPLC system with the use of a Kromasil C18 column (4.6 mm × 250 mm, 5um). <sup>1</sup>H NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 MHz. Chemical shifts (δ) are expressed in parts per million (ppm) with TMS as an internal standard. Multiplicities are given as s (singlet), d (doublet), dd (double–doublet), t (triplet), q (quartet), m (multiplet), and br (broad signal). MS spectral data were obtained on an Agilent 1100 series with UV detection at 254 nm using electrospray ionization. Thin layer chromatography (TLC) was conducted on aluminum sheet silica gel Merck 60F254. The spots were visualized using ultraviolet light.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 1-Methyl-4-(4-nitrophenyl)piperazine (<b>3</b>)</h4><div class="NLM_p last">A solution of 4-fluoronitrobenzene (10 g, 70.9 mmol), and K<sub>2</sub>CO<sub>3</sub> (10.76 g, 78.1 mmol) in DMSO (15 mL) was stirred at room temperature for 0.5 h. Subsequently, 1-methylpiperazine (8 mL, 70.9 mmol) was added dropwise, and the resulting reaction mixture was stirred at room temperature for 6 h. The mixture was then poured into ice–water. A yellow precipitate formed and was collected by filtration to give <b>3</b> (13.3 g, 85% yield, 98% HPLC purity): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 8.04 (d, <i>J</i> = 8.0 Hz, 2H), 7.02 (d, <i>J</i> = 8.0 Hz, 2H), 3.44 (t, <i>J</i> = 6.0 Hz, 4H), 2.51 (t, <i>J</i> = 6.0 Hz, 4H), 2.12 (s, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 222.41 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-(4-Methylpiperazin-1-yl)phenylamine (<b>4</b>)</h4><div class="NLM_p last">Compound <b>3</b> (5 g, 22.6 mmol) was dissolved in ethanol (150 mL), and to this solution was added 10% Pd/C (0.5 g). The reaction mixture was stirred at room temperature under an atmosphere of H<sub>2</sub> for 9 h. After completion of the reaction, the resulting mixture was filtered through Celite, and the filtered catalyst was washed with ethanol. The filtrate was concentrated under high vacuum to afford compound <b>4</b> as a fuchsia solid (3.6 g, 85% yield, 96% HPLC purity): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 6.67 (d, <i>J</i> = 8.8 Hz, 2H), 6.48 (d, <i>J</i> = 8.8 Hz, 2H), 4.52 (s, 2H), 2.89–2.87 (m, 4H), 2.50–2.48 (m, 4H), 2.19 (s, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 192.41 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Chloro-5-nitropyrimidin-4-amine (<b>6a</b>)</h4><div class="NLM_p last">2,4-Dichloro-5-nitropyrimidine (5 g, 26 mmol) and DIEA (4.7 mL, 30.9 mmol) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (300 mL) and cooled to −60 °C. Ammonium hydroxide (3.0 mL, 78 mmol) was added dropwise. The reaction mixture was stirred at −60 °C for about 1 h. Then the cooling bath was removed, and the reaction mixture was stirred at room temperature for about 0.5 h. A yellow precipitate formed and was collected by filtration, rinsing with EtOH, to give compound <b>6a</b> (4 g, 90% yield, 95% HPLC purity): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.20 (s, 1H), 9.02 (s, 1H), 8.60 (s, 1H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 175.8 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure for the Preparation of the Compounds 6b–e</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-Chloro-<i>N</i>-methyl-5-nitropyrimidin-4-amine (<b>6b</b>)</h4><div class="NLM_p last">2,4-Sichloro-5-nitropyrimidine (5 g, 26 mmol) and DIEA (4.7 mL, 30.9 mmol) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (300 mL) and cooled to −60 °C. A solution of methylamine (1.2 mL, 28.6 mmol) in water was added dropwise. The reaction mixture was stirred at −60 °C for about 1 h. TLC showed that the reaction is complete. Then the solvent was removed, and the resultant residue was chromatographed over silica gel, eluting with petroleum ether to afford the desired product <b>6b</b> (4.1 g, 85% yield, 97% HPLC purity): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 9.05 (s, 1H), 8.41 (s, 1H), 3.22 (s, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 189.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-Chloro-<i>N</i>-cyclopropyl-5-nitropyrimidin-4-amine (<b>6c</b>):</h4><div class="NLM_p last">yield, 4.1 g (75%, 97% HPLC purity); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 8.84 (s, 1H), 7.35 (s, 1H), 3.84 (m, 1H), 1.36 (m, 4H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 215.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-Chloro-<i>N</i>-isopropyl-5-nitropyrimidin-4-amine (<b>6d</b>):</h4><div class="NLM_p last">yield, 3.3 g (90%, 97% HPLC purity); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 9.03 (s, 1H), 8.24 (s, 1H), 4.53 (m, 1H), 1.34 (d, <i>J</i> = 6.8 Hz, 6H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 217.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-Chloro-<i>N</i>-cyclopentyl-5-nitropyrimidin-4-amine (<b>6e</b>):</h4><div class="NLM_p last">yield, 4.6 g (75%, 97% HPLC purity); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 9.03 (s, 1H), 8.38 (s, 1H), 4.59 (m, 1H), 2.21–2.13 (m, 2H), 1.85–1.72 (m, 4H), 1.71–1.53 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 243.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-Chloro-<i>N</i>-cyclohexyl-5-nitropyrimidin-4-amine (<b>6f</b>):</h4><div class="NLM_p last">yield, 3.6 g (76%, 97% HPLC purity); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 9.03 (s, 1H), 7.26 (s, 1H), 4.25–4.23 (m, 1H), 2.05–2.03 (m, 2H), 1.81–1.78 (m, 2H), 1.50–1.36 (m, 6H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 257.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-Chloro-5-nitro-<i>N</i>-phenylpyrimidin-4-amine (<b>6g</b>)</h4><div class="NLM_p last">To a solution of 2,4-dichloro-5-nitropyrimidine (5 g, 25.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added <i>N</i>,<i>N</i>-diisopropylethylamine (4.3 mL, 25.7 mmol) and aniline (2.4 mL, 25.7 mmol) at 0 °C. The reaction mixture was stirred for 5 h at room temperature, and then saturated salt water (200 mL) was added. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (300 mL). The combined organic layer was dried over MgSO<sub>4</sub> and concentrated to dryness. The residue was purified by recrystallization from diethyl ether: yield, 5.8 g (90%, 96% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.45 (s, 1H), 9.10 (s, 1H), 7.54 (d, <i>J</i> = 8.0 Hz, 2H), 7.45 (t, <i>J</i> = 7.6 Hz, 2H), 7.29 (t, <i>J</i> = 7.6 Hz, 1H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 251.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-Chloro-<i>N</i>-(3,5-dimethylphenyl)-5-nitropyrimidin-4-amine (6h)</h4><div class="NLM_p last">The title compound was prepared from <b>5</b> and 3,5-dimethylaniline using the procedure previously described for compound <b>6f</b> and was purified by recrystallization from diethyl ether: yield, 5.7 g (89%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.32 (s, 1H), 9.14 (s, 1H), 7.31 (s, 2H), 6.94 (s, 1H), 2.30 (s, 6H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 279.9 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> General Procedure for the Synthesis of Compounds 7a–7h</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i><sup>2</sup>-(4-(4-Methylpiperazin-1-yl)phenyl)-5-nitropyrimidine-2,4-diamine (<b>7a</b>)</h4><div class="NLM_p last">A solution of <b>6a</b> (3 g, 17.2 mmol) and <b>4</b> (3.3 g, 17.2 mmol) in <i>n</i>-butanol (200 mL) was stirred at 90 °C for 5 h. After this time, the reaction mixture was cooled to room temperature. The resulting precipitate was collected by filtration, rinsing with EtOH, to give compound <b>7a</b> as its hydrochloride salt (4.3 g, 75% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 9.07 (s, 1H), 8.52 (s, 2H), 8.40 (s, 1H), 7.55 (m, 2H), 7.10 (m, 2H), 3.31 (t, <i>J</i> = 4.8 Hz, 4H), 2.81 (t, <i>J</i> = 4.8 Hz, 4H), 2.30 (s, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 330.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i><sup>4</sup>-Methyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-5-nitropyrimidine-2,4-diamine (<b>7b</b>):</h4><div class="NLM_p last">yield, 2.6 g (75%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 9.11 (s, 1H), 8.34 (s, 1H), 7.59 (s, 1H), 7.51 (m, 2H), 7.23 (m, 2H), 4.21 (s, 3H), 3.15 (t, <i>J</i> = 4.8 Hz, 4H), 2.87 (t, <i>J</i> = 4.8 Hz, 4H), 2.48 (s, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 344.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i><sup>4</sup>-Cyclopropyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-5-nitropyrimidine-2,4-diamine (<b>7c</b>):</h4><div class="NLM_p last">yield, 2.6 g (71%, 96% HPLC purity); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 9.08 (s, 1H), 8.39 (s, 1H), 7.90 (s, 1H), 7.58 (m, 2H), 6.94 (m, 2H), 4.32 (m, 1H), 3.05 (t, <i>J</i> = 4.8 Hz, 4H), 2.90 (t, <i>J</i> = 4.8 Hz, 4H), 2.67 (s, 3H), 1.39 (m, 4H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 370.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i><sup>4</sup>-Isopropyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-5-nitropyrimidine-2,4-diamine (<b>7d</b>):</h4><div class="NLM_p last">yield, 2.8 g (73%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 9.02 (s, 1H), 8.42 (s, 1H), 7.63 (s, 1H), 7.51 (m, 2H), 6.95 (m, 2H), 4.41 (m, 1H), 3.22 (t, <i>J</i> = 4.8 Hz, 4H), 2.61 (t, <i>J</i> = 4.8 Hz, 4H), 2.37 (s, 3H), 1.33 (d, <i>J</i> = 6.4 Hz, 6H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 372.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i><sup>4</sup>-Cyclopentyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-5-nitropyrimidine-2,4-diamine (<b>7e</b>):</h4><div class="NLM_p last">yield, 2.2 g (71%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 9.03 (s, 1H), 8.47 (s, 1H), 7.69 (s, 1H), 7.51 (m, 2H), 7.11 (m, 2H), 4.43 (m, 1H), 3.28 (t, <i>J</i> = 4.8 Hz, 4H), 2.67 (t, <i>J</i> = 4.8 Hz, 4H), 2.45 (s, 3H), 2.23–2.15 (m, 2H), 1.86–1.74 (m, 4H), 1.72–1.50 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 398.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i><sup>4</sup>-Cyclohexyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-5-nitropyrimidine-2,4-diamine (<b>7f</b>):</h4><div class="NLM_p last">yield, 2.6 g (67%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 10.28 (s, 1H), 8.95 (s, 1H), 8.48 (s, 1H), 7.67 (d, <i>J</i> = 8.0 Hz, 2H), 6.94 (d, <i>J</i> = 8.0 Hz, 2H), 4.04 (m, 1H), 3.01 (s, 3H), 2.72 (s, 4H), 2.41 (s, 4H), 1.97 (s, 2H), 1.76–1.74 (m, 2H), 1.65–1.62 (m, 2H), 1.43–1.40 (m, 4H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 412.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i><sup>2</sup>-(4-(4-Methylpiperazin-1-yl)phenyl)-5-nitro-<i>N</i><sup>4</sup>-phenylpyrimidine-2,4-diamine (<b>7g</b>):</h4><div class="NLM_p last">yield, 2.8 g (78%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.37 (s, 1H), 10.36 (s, 1H), 9.07 (s, 1H), 7.58 (d, <i>J</i> = 7.6 Hz, 2H), 7.43 (d, <i>J</i> = 7.6 Hz, 2H), 7.40 (m, 1H), 7.30–7.28 (m, 2H), 6.82 (d, <i>J</i> = 8.4 Hz, 2H), 3.30 (m, 4H), 2.79 (s, 3H), 2.49 (m, 4H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 406.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i><sup>4</sup>-(3,5-Dimethylphenyl)-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-5-nitropyrimidine-2,4-diamine (<b>7h</b>):</h4><div class="NLM_p last">yield, 2.1 g (76%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.37 (s, 1H), 10.33 (s, 1H), 9.07 (s, 1H), 7.50 (d, <i>J</i> = 8.8 Hz, 2H), 7.24 (s, 2H), 6.89 (s, 1H), 6.87 (d, <i>J</i> = 8.8 Hz, 2H), 3.76–3.73 (m, 2H), 3.50–3.48 (m, 2H), 3.16–3.14 (m, 2H), 3.01–2.97 (m, 2H), 2.82 (s, 3H), 2.26 (s, 6H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 434.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i><sup>2</sup>-(4-(4-Methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>9a</b>)</h4><div class="NLM_p">To a solution of the hydrochloride salt of <b>7a</b> (3 g, 8.2 mmol) in MeOH (60 mL) was added 10% Pd/C (300 mg), and the resulting suspension was stirred at 50 °C under an atmospheric pressure of H<sub>2</sub> for 6 h. Then the catalyst was filtered over dicalite. The filtrate was concentrated under high vacuum to afford the product <b>8a</b> as a black solid. This material was not purified but used directly in the next step.</div><div class="NLM_p last">A suspension of compound <b>8a</b> (1 g, 3.34 mmol), EDCI (0.8 g, 3.78 mmol), DIEA (0.6 mL, 3.78 mmol), and phenyl isothiocyanate (0.5 mL, 3.78 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was refluxed for 12 h until TLC showed that the reaction was complete. The reaction mixture was evaporated under reduced pressure, and the residue was chromatographed over silica gel eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (20:1) to give a pale yellow solid, which was further washed with cold ethanol to afford pure product <b>9a</b> (0.64 g, 48% yield, 95% HPLC purity): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.89 (s, 1H), 9.93 (s, 1H), 8.77 (s, 1H), 8.20 (s, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 2H), 7.34 (t, <i>J</i> = 6.8 Hz, 2H), 7.30 (d, <i>J</i> = 7.2 Hz, 2H), 7.00 (s, 1H), 6.87 (d, <i>J</i> = 8.8 Hz, 2H), 3.04 (t, <i>J</i> = 4.4 Hz, 4H), 2.46 (t, <i>J</i> = 4.4 Hz, 4H), 2.23 (s, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 401.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 9-Methyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>9b</b>)</h4><div class="NLM_p last">An analogous reaction to that described for compound <b>9a</b>, but starting with <b>7b</b>, was used: yield, 0.7 g (40%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.11 (s, 1H), 9.02 (s, 1H), 8.32 (s, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 2H), 7.67 (d, <i>J</i> = 8.8 Hz, 2H), 7.33 (t, <i>J</i> = 8.0 Hz, 2H), 6.98 (t, <i>J</i> = 7.2 Hz, 1H), 6.87 (d, <i>J</i> = 8.0 Hz, 2H), 3.66 (s, 3H), 3.04 (m, 4H), 2.46 (m, 4H), 2.22 (s, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 415.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 9-Cyclopropyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>9c</b>)</h4><div class="NLM_p last">An analogous reaction to that described for compound <b>9a</b>, but starting with <b>7c</b>, was used: yield, 0.9 g (41%, 97% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.00 (s, 1H), 8.87 (s, 1H), 8.31 (s, 1H), 7.89 (d, <i>J</i> = 8.0 Hz, 2H), 7.69 (d, <i>J</i> = 8.0 Hz, 2H), 7.34 (t, <i>J</i> = 8.0 Hz, 2H), 7.00 (t, <i>J</i> = 8.0 Hz, 1H), 6.88 (d, <i>J</i> = 8.0 Hz, 2H), 4.34 (m, 1H), 3.18–3.17 (br, 4H), 2.48–2.47 (br, 4H), 2.23 (s, 3H), 1.26–1.24 (m, 2H), 1.23–1.17 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 441.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 9-Isopropyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>9d</b>)</h4><div class="NLM_p last">An analogous reaction to that described for compound <b>9a</b>, but starting with <b>7d</b>, was used: yield, 0.6 g (37%, 96% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.09 (s, 1H), 9.07 (s, 1H), 8.36 (s, 1H), 7.83 (d, <i>J</i> = 8.0 Hz, 2H), 7.69 (d, <i>J</i> = 9.2 Hz, 2H), 7.33 (m, 2H), 6.97 (m, 3H), 4.92 (m, 1H), 3.44 (br, 4H), 3.17 (br, 4H), 2.81 (s, 3H), 1.67 (d, <i>J</i> = 6.8 Hz, 6H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 443.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 9-Cyclopentyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>9e</b>)</h4><div class="NLM_p last">An analogous reaction to that described for compound <b>9a</b>, but starting with <b>7e</b>, was used: yield, 0.6 g (48%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 8.99 (s, 1H), 8.97 (s, 1H), 8.35 (s, 1H), 7.81 (d, <i>J</i> = 8.0 Hz, 2H), 7.61 (d, <i>J</i> = 8.0 Hz, 2H), 7.33 (t, <i>J</i> = 8.0 Hz, 2H), 6.98 (t, <i>J</i> = 8.0 Hz, 1H), 6.87 (d, <i>J</i> = 8.0 Hz, 2H), 5.02–4.91 (m, 1H), 3.06–3.03 (m, 4H), 2.50–2.46 (m, 4H), 2.44 (s, 2H), 2.22 (s, 3H), 2.05 (s, 4H), 1.70 (s, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 469.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 9-Cyclohexyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>9f</b>)</h4><div class="NLM_p last">An analogous reaction to that described for compound <b>9a</b>, but starting with <b>7f</b>, was used: yield, 0.28 g (35%, 96% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.04 (s, 1H), 8.99 (s, 1H), 8.34 (s, 1H), 7.80 (d, <i>J</i> = 8.0 Hz, 2H), 7.67 (d, <i>J</i> = 8.0 Hz, 2H), 7.33 (t, <i>J</i> = 8.0 Hz, 2H), 6.98 (t, <i>J</i> = 8.0 Hz, 1H), 6.87 (d, <i>J</i> = 8.0 Hz, 2H), 5.01–4.81 (m, 1H), 3.05 (s, 4H), 2.47 (s, 6H), 2.23 (s, 3H), 1.92–1.90 (m, 2H), 1.84–1.81 (m, 2H), 1.80–1.78 (m, 2H), 1.48–1.44 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 483.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N</i><sup>2</sup>-(4-(4-Methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8,9</sup>-diphenyl-9<i>H</i>-purine-2,8-diamine (<b>9g</b>)</h4><div class="NLM_p last">An analogous reaction to that described for compound <b>9a</b>, but starting with <b>7g</b>, was used: yield, 1.2 g (48%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.07 (s, 1H), 8.77 (s, 1H), 8.45 (s, 1H), 7.80 (d, <i>J</i> = 8.0 Hz, 2H), 7.67 (d, <i>J</i> = 8.0 Hz, 2H), 7.56–7.46 (m, 5H), 7.30 (t, <i>J</i> = 8.0 Hz, 2H), 6.98 (t, <i>J</i> = 8.0 Hz, 1H), 6.85 (s, 1H), 6.82 (s, 1H), 3.18 (s, 4H), 2.93 (s, 4H), 2.65 (s, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 477.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 9-(3,5-Dimethylphenyl)-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>9h</b>)</h4><div class="NLM_p last">An analogous reaction to that described for compound <b>9a</b>, but starting with <b>7h</b>, was used: yield, 1.7 g (48%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.06 (s, 1H), 8.70 (s, 1H), 8.42 (s, 1H), 7.81 (d, <i>J</i> = 8.0 Hz, 2H), 7.60 (d, <i>J</i> = 8.0 Hz, 2H), 7.31 (t, <i>J</i> = 8.0 Hz, 2H), 7.21(s, 3H), 6.82 (t, <i>J</i> = 8.0 Hz, 1H), 6.81 (d, <i>J</i> = 8.0 Hz, 2H), 3.12 (s, 4H), 2.78 (s, 4H), 2.45 (s, 3H), 2.40 (s, 6H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 505.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-(4-Nitrophenyl)morpholine (<b>10a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>2</b> and morpholine using the procedure previously described for compound <b>3</b>: yield, 6.4 g (85%, 96% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 8.19 (d, <i>J</i> = 8.8 Hz, 2H), 7.58 (d, <i>J</i> = 8.8 Hz, 2H), 2.38 (br, 4H), 2.33 (br, 4H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 209.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 4-Methyl-1-(4-nitrophenyl)piperidine (<b>10b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>2</b> and 4-methylpiperidine using the procedure previously described for compound <b>3</b>: yield, 5.4 g (70%, 96% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 8.02 (d, <i>J</i> = 8.0 Hz, 2H), 6.99 (d, <i>J</i> = 8.0 Hz, 2H), 4.02 (m, 2H), 2.96 (m, 2H), 1.72 (s, 1H), 1.66 (m, 2H), 1.12 (m, 2H), 0.91 (d, <i>J</i> = 4.0 Hz, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 221.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 2-(4-Nitrophenylamino)ethanol (<b>10c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>2</b> and ethanolamine using the procedure previously described for compound <b>3</b>: yield, 5.1 g (80%, 96% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 7.97 (d, <i>J</i> = 8.0 Hz, 2H), 7.29 (m, 1H), 6.65 (d, <i>J</i> = 8.0 Hz, 2H), 4.80 (m, 1H), 3.57 (m, 2H), 3.23 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 183.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i><sup>4</sup>-Cyclopentyl-<i>N</i><sup>2</sup>-(4-morpholinophenyl)-5-nitropyrimidine-2,4-diamine (<b>12a</b>)</h4><div class="NLM_p">A solution of compound <b>10a</b> (3 g, 14.4 mmol) in ethanol (250 mL) was purged with N<sub>2</sub>, and 10% Pd/C (0.3 g) was added. The mixture was placed under H<sub>2</sub> (1 atm) for 9 h. The mixture was purged with N<sub>2</sub> and filtered through a pad of Celite, rinsing with ethanol. The filtrate was concentrated to give compound <b>11a</b>. This compound was not purified but used directly in the next step.</div><div class="NLM_p last">A solution of <b>6e</b> (3 g, 12.4 mmol) and <b>11a</b> (2.2 g, 12.4 mmol) in <i>n</i>-butanol (200 mL) was stirred at 90 °C for 5 h. The reaction mixture was cooled to room temperature. The resulting precipitate was collected by filtration, rinsing with EtOH, to give compound <b>12a</b> as its hydrochloride salt (2.7 g, 51% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.29 (s, 1H), 8.94 (s, 1H), 8.52–8.50 (br, 1H), 7.69 (d, <i>J</i> = 8.0 Hz, 2H), 6.94 (d, <i>J</i> = 12.0 Hz, 2H), 4.45–4.44 (br, 1H), 3.73 (t, <i>J</i> = 6.0 Hz, 4H), 3.08 (t, <i>J</i> = 6.0 Hz, 4H), 2.06–2.04 (br, 2H), 1.73–1.71 (br, 2H), 1.62 (s, 4H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 385.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i><sup>4</sup>-Cyclopentyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperidin-1-yl)phenyl)-5-nitropyrimidine-2,4-diamine (<b>12b</b>)</h4><div class="NLM_p last">Compound <b>12b</b> was prepared following the procedure described for <b>12a</b>, substituting <b>10b</b> for <b>10a</b>: yield, 3.1 g (70%, 96% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.27 (s, 1H), 8.93 (s, 1H), 8.51 (br, 1H), 7.66 (d, <i>J</i> = 8.0 Hz, 2H), 6.93 (d, <i>J</i> = 8.0 Hz, 2H), 4.45 (s, 1H), 3.62 (br, 2H), 2.63 (br, 2H), 2.05 (m, 2H), 1.73–1.71 (m, 4H), 1.70–1.68 (m, 4H), 1.49 (br, 1H), 1.26–1.23 (m, 2H), 0.93 (d, <i>J</i> = 4.0 Hz, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 397.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 2-(4-(4-(Cyclopentylamino)-5-nitropyrimidin-2-ylamino)phenylamino)ethanol (<b>12c</b>)</h4><div class="NLM_p last">Compound <b>12c</b> was prepared following the procedure described for <b>12a</b>, substituting <b>10c</b> for <b>10a</b>: yield, 3.7 g (70%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.60 (s, 1H), 8.99 (s, 1H), 8.51 (s, 1H), 7.92 (s, 2H), 7.57 (d, <i>J</i> = 7.6 Hz, 2H), 5.04–4.71 (br, 3H), 4.48 (s, 2H), 3.72 (s, 2H), 2.06 (s, 2H), 1.66 (s, 2H), 1.64 (s, 4H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 359.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>N</i><sup>4</sup>-Cyclopentyl-5-nitro-<i>N</i><sup>2</sup>-phenylpyrimidine-2,4-diamine (<b>12d</b>)</h4><div class="NLM_p last">A solution of <b>6e</b> (3 g, 12.4 mmol) and aniline (1.2 g, 12.4 mmol) in <i>n</i>-butanol (200 mL) was stirred at 90 °C for 5 h. The reaction mixture was cooled to room temperature. The resulting precipitate was collected by filtration, rinsing with EtOH, to give compound <b>12d</b> (2.6 g, 70% yield, 95% HPLC purity): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.43 (s, 1H), 8.99 (s, 1H), 8.50 (s, 1H), 7.80 (d, <i>J</i> = 8.0 Hz, 2H), 7.35 (t, <i>J</i> = 8.0 Hz, 2H), 7.08 (t, <i>J</i> = 8.0 Hz, 1H), 4.48 (s, 1H), 2.06–2.04 (m, 2H) 1.73–1.71 (m, 2H), 1.66–1.62 (m, 4H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 300.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>-(4-(4-(Cyclopentylamino)-5-nitropyrimidin-2-ylamino)phenyl)acetamide (<b>12e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>6e</b> and <i>N</i>-(4-aminophenyl)acetamide using the procedure previously described for compound <b>12d</b>: yield, 4.5 g (72%, 96% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.39 (s, 1H), 9.67 (s, 1H), 8.97 (s, 1H), 8.50 (s, 1H), 7.70 (d, <i>J</i> = 8.4 Hz, 2H), 7.55 (d, <i>J</i> = 8.4 Hz, 2H), 4.25 (s, 1H), 2.50 (s, 3H), 2.05 (s, 2H), 1.73 (s, 2H), 1.62 (s, 4H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 357.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 9-Cyclopentyl-<i>N</i><sup>2</sup>-(4-morpholinophenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>14a</b>)</h4><div class="NLM_p">To a solution of compound <b>12a</b> (3 g, 7.8 mmol) in MeOH (60 mL) was added 10% Pd/C (300 mg), and the resulting suspension was stirred at 50 °C under an atmospheric pressure of H<sub>2</sub> for 6 h. Then the catalyst was filtered over dicalite. The filtrate was concentrated under high vacuum to afford the product <b>13a</b> as a black solid. This material was not purified but used directly in the next step.</div><div class="NLM_p last">A suspension of compound <b>13a</b> (1 g, 2.82 mmol), EDCI (0.6 g, 3.11 mmol), DIEA (0.5 mL, 3.78 mmol), and phenyl isothiocyanate (0.4 mL, 3.78 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was refluxed for 12 h until TLC showed that the reaction was complete. The reaction mixture was evaporated under reduced pressure, and the residue was chromatographed over silica gel eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (70:1) to give a white solid, which was further washed with diethyl ether to afford pure product <b>14a</b> (0.76 g, 60% yield, 95% HPLC purity): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.00 (s, 1H), 8.99 (s, 1H), 8.34 (s, 1H), 7.81 (d, <i>J</i> = 8.0 Hz, 2H), 7.63 (d, <i>J</i> = 8.8 Hz, 2H), 7.33 (t, <i>J</i> = 8.0 Hz, 2H), 6.99–6.98 (m, 1H), 6.88 (d, <i>J</i> = 8.0 Hz, 2H), 4.97–4.93 (m, 1H), 3.74 (t, <i>J</i> = 4.0 Hz, 4H), 3.02 (t, <i>J</i> = 4.0 Hz, 4H), 2.47 (s, 2H), 2.05 (s, 4H), 1.70 (s, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 456.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 9-Cyclopentyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperidin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine (<b>14b</b>)</h4><div class="NLM_p last">Compound <b>14b</b> was prepared following the procedure described for <b>14a</b>, substituting <b>12b</b> for <b>12a</b>: yield, 0.76 g (52%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 8.98 (s, 1H), 8.94 (s, 1H), 8.34 (s, 1H), 7.81 (d, <i>J</i> = 8.0 Hz, 2H), 7.59 (d, <i>J</i> = 8.0 Hz, 2H), 7.33 (t, <i>J</i> = 8.0 Hz, 2H), 6.98 (t, <i>J</i> = 8.0 Hz, 1H), 6.86 (d, <i>J</i> = 8.0 Hz, 2H), 5.02–4.91 (m, 1H), 2.50 (m, 1H), 2.04–1.99 (m, 4H), 1.71–1.68 (m, 4H), 0.94 (d, <i>J</i> = 4.0 Hz, 3H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 468.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 2-(4-(9-Cyclopentyl-8-(phenylamino)-9<i>H</i>-purin-2-ylamino)phenylamino)ethanol (<b>14c</b>)</h4><div class="NLM_p last">Compound <b>14c</b> was prepared following the procedure described for <b>14a</b>, substituting <b>12c</b> for <b>12a</b>: yield, 0.66 g (56%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.46 (s, 1H), 9.05 (s, 1H), 8.69 (s, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 2H), 7.82 (d, <i>J</i> = 8.0 Hz, 2H), 7.30–7.23 (m, 5H), 7.10–7.07 (m, 1H), 7.01–6.98 (m, 1H), 4.95–4.91 (m, 1H), 4.16 (t, <i>J</i> = 7.2 Hz, 2H), 3.67 (t, <i>J</i> = 8.0 Hz, 2H), 2.51 (br, 2H), 2.06 (br, 4H), 1.71–1.70 (br, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 430.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 9-Cyclopentyl-<i>N</i><sup>2</sup>,<i>N</i><sup>8</sup>-diphenyl-9<i>H</i>-purine-2,8-diamine (<b>14d</b>)</h4><div class="NLM_p last">Compound <b>14d</b> was prepared following the procedure described for <b>14a</b>, substituting <b>12d</b> for <b>12a</b>: yield, 0.36 g (61%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.25 (s, 1H), 9.04 (s, 1H), 8.41 (s, 1H), 7.83 (d, <i>J</i> = 8.0 Hz, 2H), 7.78 (d, <i>J</i> = 8.0 Hz, 2H), 7.34 (t, <i>J</i> = 8.0 Hz, 2H), 7.26 (t, <i>J</i> = 8.0 Hz, 2H), 6.99 (t, <i>J</i> = 8.0 Hz, 1H), 6.89 (t, <i>J</i> = 8.0 Hz, 1H), 5.02–4.93 (m, 1H), 2.49 (s, 2H), 2.06 (s, 4H), 1.71 (s, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 371.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-(4-(9-Cyclopentyl-8-(phenylamino)-9<i>H</i>-purin-2-ylamino)phenyl)acetamide (<b>14e</b>)</h4><div class="NLM_p last">Compound <b>14e</b> was prepared following the procedure described for <b>14a</b>, substituting <b>12e</b> for <b>12a</b>: yield, 0.54 g (41%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.76 (s, 1H), 9.17 (s, 1H), 9.02 (s, 1H), 8.38 (s, 1H), 7.82 (d, <i>J</i> = 8.0 Hz, 2H), 7.67 (d, <i>J</i> = 8.9 Hz, 2H), 7.45 (d, <i>J</i> = 8.0 Hz, 2H), 7.33 (t, <i>J</i> = 8.0 Hz, 2H), 6.99 (t, <i>J</i> = 7.6 Hz, 1H), 4.99–4.93 (m, 1H), 2.50 (s, 4H), 2.04 (s, 3H), 1.99 (s, 2H), 1.71 (s, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 428.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 1-Nitryl-3-isothiocyanato-benzene (<b>17a</b>)</h4><div class="NLM_p last">To a solution of <b>15a</b> (1.5 g, 10.9 mmol) in EtOH (15 mL) were added CS<sub>2</sub> (1.9 mL, 32.7 mmol) and DABCO (7.36 g, 65.4 mmol). The reaction mixture was stirred at room temperature overnight. The resulting precipitate was collected by filtration, washed with ice-cold ethanol, and dried to yield <b>16a</b> as a pale yellow solid, which was used in the next step without further characterization and purification. Triphosgene (1.6 g, 5.5 mmol) was added slowly to a solution of <b>16a</b> in CH<sub>2</sub>Cl<sub>2</sub> at 0 °C. The reaction mixture was stirred at this temperature for an additional 1 h and then heated at 40 °C for 4 h; the reaction was quenched with water. The crude was extracted with CH<sub>2</sub>Cl<sub>2</sub> and then dried over MgSO<sub>4</sub>. Then the organic layer was concentrated, and the resultant residue was chromatographed over silica gel, eluting with petroleum ether to afford the desired product <b>17a</b> (1.1 g, 58% yield): MS (ESI, positive ion), <i>m</i>/<i>z</i> 181.41 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Compounds 17b–j were prepared from 15b–j in a manner identical to the preparation of 17a</h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 1-Alkynyl-3-isothiocyanatobenzene (<b>17b</b>):</h4><div class="NLM_p last">yield, 70%; MS (ESI, positive ion), <i>m</i>/<i>z</i> 160.10 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 1-Methyl-3-isothiocyanatobenzene (<b>17c</b>):</h4><div class="NLM_p last">yield, 61%; MS (ESI, positive ion), <i>m</i>/<i>z</i> 150.30 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 1-Hydroxy-3-isothiocyanatobenzene (<b>17d</b>):</h4><div class="NLM_p last">yield, 56%; MS (ESI, positive ion), <i>m</i>/<i>z</i> 152.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 1-Chloro-3-isothiocyanatobenzene (<b>17e</b>):</h4><div class="NLM_p last">yield, 58%; MS (ESI, positive ion), <i>m</i>/<i>z</i> 170.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 1-Bromo-4-isothiocyanatobenzene (<b>17f</b>):</h4><div class="NLM_p last">yield, 50%; MS (ESI, positive ion), <i>m</i>/<i>z</i> 215.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 1-Fluoro-3-bromo-6-isothiocyanatobenzene (<b>17g</b>):</h4><div class="NLM_p last">yield, 52%; MS (ESI, positive ion), <i>m</i>/<i>z</i> 233.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 1,4-Dichloro-2-isothiocyanatobenzene (<b>17h</b>):</h4><div class="NLM_p last">yield, 67%; MS (ESI, positive ion), <i>m</i>/<i>z</i> 205.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> <i>N</i>-(4-Chlorophenyl)-3-isothiocyanatobenzamide (<b>17i</b>):</h4><div class="NLM_p last">yield, 63%; MS (ESI, positive ion), <i>m</i>/<i>z</i> 289.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> <i>N</i>-(3-Isothiocyanatophenyl)benzamide (<b>17j</b>):</h4><div class="NLM_p last">yield, 60%; MS (ESI, positive ion), <i>m</i>/<i>z</i> 255.6 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Compounds 18a–j were prepared by condensation of 8e with various substituted phenyl isothiocyanates (17a–j) using the procedure previously described for compound 9e and were purified by column chromatography</h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 9-Cyclopentyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-(3-nitrophenyl)-9<i>H</i>-purine-2,8-diamine (<b>18a</b>):</h4><div class="NLM_p last">yield, 1.1 g (46%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.54 (s, 1H), 9.05 (s, 1H), 8.82 (s, 1H), 8.45 (s, 1H), 8.32 (d, <i>J</i> = 7.6 Hz, 1H), 7.83 (d, <i>J</i> = 8.0 Hz, 1H), 7.63 (s, 1H), 7.61 (d, <i>J</i> = 8.0 Hz, 2H), 6.95 (d, <i>J</i> = 8.8 Hz, 2H), 4.98–4.94 (m, 1H), 3.05 (s, 4H), 2.48 (s, 2H), 2.48 (s, 4H), 2.23 (s, 3H), 2.06 (s, 4H), 1.71 (s, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 514.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 9-Cyclopentyl-<i>N</i><sup>8</sup>-(3-ethynylphenyl)-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-9<i>H</i>-purine-2,8-diamine (<b>18b</b>):</h4><div class="NLM_p last">yield, 1.3 g (41%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.26 (s, 1H), 9.13 (s, 1H), 8.43 (s, 1H), 8.09 (s, 1H), 7.85 (d, <i>J</i> = 8.0 Hz, 1H), 7.68 (d, <i>J</i> = 8.0 Hz, 2H), 7.35 (t, <i>J</i> = 8.0 Hz, 1H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 6.95 (d, <i>J</i> = 8.0 Hz, 2H), 5.02–4.98 (m, 1H), 4.20 (s, 1H), 3.70 (br, 2H), 3.47 (br, 2H), 3.18 (br, 2H), 3.00 (br, 2H), 2.83 (s, 3H), 2.46 (br, 2H), 2.05 (br, 4H), 1.71 (br, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 493.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 9-Cyclopentyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-<i>m</i>-tolyl-9<i>H</i>-purine-2,8-diamine (<b>18c</b>):</h4><div class="NLM_p last">yield, 1.3 g (42%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.08 (s, 1H), 9.02 (s, 1H), 8.37 (s, 1H), 7.68–7.62 (m, 4H), 7.22 (m, 1H), 6.93 (d, <i>J</i> = 8.8 Hz, 2H), 6.80 (d, <i>J</i> = 7.6 Hz, 1H), 4.99 (m, 1H), 3.67 (m, 2H), 3.44 (m, 2H), 3.03 (m, 4H), 2.81 (s, 3H), 2.45 (m, 2H), 2.31 (s, 3H), 2.04 (m, 4H), 1.69 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 483.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 3-(9-Cyclopentyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)-9<i>H</i>-purin-8-ylamino)phenol (<b>18d</b>):</h4><div class="NLM_p last">yield, 0.5 g (36%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.36 (s, 1H), 9.07 (s, 1H), 8.93 (s, 1H), 8.35 (s, 1H), 7.67 (d, <i>J</i> = 9.2 Hz, 2H), 7.38 (s, 1H), 7.16 (d, <i>J</i> = 9.2 Hz, 1H), 7.10–7.08 (m, 1H), 6.93 (d, <i>J</i> = 9.2 Hz, 2H), 6.39 (s, 1H), 4.98–4.96 (m, 1H), 3.43 (m, 2H), 3.34 (m, 2H), 3.16 (m, 4H), 2.80 (s, 3H), 2.46 (m, 2H), 2.04 (m, 4H), 1.69 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 485.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> <i>N</i><sup>8</sup>-(3-Chlorophenyl)-9-cyclopentyl-<i>N</i><sub>2</sub>-(4-(4-methylpiperazin-1-yl)phenyl)-9<i>H</i>-purine-2,8-diamine (<b>18e</b>):</h4><div class="NLM_p last">yield, 0.7 g (45%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.38 (s, 1H), 9.13 (s, 1H), 8. 44 (s, 1H), 8.11 (s, 1H), 7.75 (d, <i>J</i> = 8.0 Hz, 1H), 7.65 (d, <i>J</i> = 8.4 Hz, 2H), 7.35 (m, 1H), 7.02 (m, 1H), 6.94 (d, <i>J</i> = 8.8 Hz, 2H), 5.01 (m, 1H), 3.43 (m, 4H), 3.10 (m, 4H), 2.82 (s, 3H), 2.45 (m, 2H), 2.05 (m, 4H), 1.70 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 505.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> <i>N</i><sup>8</sup>-(4-Bromophenyl)-9-cyclopentyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-9<i>H</i>-purine-2,8-diamine (<b>18f</b>):</h4><div class="NLM_p last">yield, 0.7 g (48%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.22 (s, 1H), 9.09 (s, 1H), 8.39 (s, 1H), 7.83 (d, <i>J</i> = 9.2 Hz, 2H), 7.66 (d, <i>J</i> = 8.0 Hz, 2H), 7.51 (d, <i>J</i> = 8.0 Hz, 2H), 6.93 (d, <i>J</i> = 8.0 Hz, 2H), 4.98–4.94 (m, 1H), 3.15 (m, 4H), 2.75 (m, 4H), 2.46 (s, 3H), 2.05 (m, 4H), 1.68 (m, 2H), 1.23 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 548.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> <i>N</i><sup>8</sup>-(4-Bromo-2-fluorophenyl)-9-cyclopentyl-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-9<i>H</i>-purine-2,8-diamine (<b>18g</b>):</h4><div class="NLM_p last">yield, 0.6 g (46%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.06 (s, 1H), 8.93 (s, 1H), 8.35 (s, 1H), 7.88–7.83 (m, 1H), 7.62 (d, <i>J</i> = 8.0 Hz, 2H), 7.59 (s, 1H), 7.40 (d, <i>J</i> = 8.0 Hz, 1H), 6.88 (d, <i>J</i> = 8.0 Hz, 2H), 4.90–4.86 (m, 1H), 3.10 (m, 4H), 2.62 (m, 4H), 2.43 (m, 2H), 2.34 (s, 3H), 2.03 (m, 4H), 1.68 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 566.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 9-Cyclopentyl-<i>N</i><sup>8</sup>-(2,5-dichlorophenyl)-<i>N</i><sup>2</sup>-(4-(4-methylpiperazin-1-yl)phenyl)-9<i>H</i>-purine-2,8-diamine (<b>18h</b>):</h4><div class="NLM_p last">yield, 0.9 g (47%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 9.02 (s, 1H), 8.62 (s, 1H), 8.37 (s, 1H), 7.91 (s, 1H), 7.59 (d, <i>J</i> = 8.4 Hz, 2H), 7.49 (d, <i>J</i> = 7.6 Hz, 1H), 7.10 (m, 1H), 6.86 (d, <i>J</i> = 9.2 Hz, 2H), 4.91 (m, 1H), 3.04 (m, 4H), 2.45 (m, 4H), 2.31 (m, 2H), 2.22 (s, 3H), 2.00 (m, 4H), 1.67 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 623.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> <i>N</i>-(4-Chlorophenyl)-3-(9-cyclopentyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)-9<i>H</i>-purin-8-ylamino)benzamide (<b>18i</b>):</h4><div class="NLM_p last">yield, 0.8 g (49%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.42 (s, 1H), 9.36 (s, 1H), 9.12 (s, 1H), 8.41 (s, 1H), 8.26 (s, 1H), 8.19 (d, <i>J</i> = 8.0 Hz, 1H), 7.84 (d, <i>J</i> = 9.2 Hz, 2H), 7.67 (d, <i>J</i> = 8.8 Hz, 2H), 7.57 (d, <i>J</i> = 7.6 Hz, 1H), 7.49 (d, <i>J</i> = 7.8 Hz, 1H), 7.42 (d, <i>J</i> = 8.8 Hz, 2H), 6.94 (d, <i>J</i> = 8.8 Hz, 2H), 4.99 (m, 1H), 3.85–3.45 (br, 2H), 3.20–2.90 (br, 4H), 2.80 (s, 3H), 2.46–2.39 (br, 4H), 2.05 (m, 4H), 1.71 (m, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 623.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>N</i>-(3-(9-Cyclopentyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)-9<i>H</i>-purin-8-ylamino)phenyl)benzamide (<b>18j</b>):</h4><div class="NLM_p last">yield, 0.8 g (49%, 95% HPLC purity); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>), δ 10.30 (s, 1H), 9.15 (s, 1H), 9.05 (s, 1H), 8.36 (s, 1H), 8.26 (s, 1H), 7.98 (d, <i>J</i> = 7.2 Hz, 2H), 7.67 (s, 1H), 7.64 (d, <i>J</i> = 8.8 Hz, 2H), 7.59 (d, <i>J</i> = 6.8 Hz, 1H), 7.55 (d, <i>J</i> = 6.8 Hz, 2H), 7.52 (s, 1H), 7.30 (d, <i>J</i> = 6.8 Hz, 1H), 6.90 (d, <i>J</i> = 8.8 Hz, 2H), 5.00 (m, 1H), 3.17–3.05 (br, 4H), 2.82 (s, 3H), 2.50–2.40 (br, 4H), 2.47 (m, 2H), 2.05 (m, 4H), 1.71–1.70 (br, 2H); MS (ESI, positive ion), <i>m</i>/<i>z</i> 588.9 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Kinase Inhibition and Binding Affinity Assays</h3><div class="NLM_p last">Kinase inhibition profiles were obtained using KinaseProfiler services provided by Millipore, and ATP concentrations used are the ATP <i>K</i><sub>m</sub> of corresponding kinases. Binding affinities were measured through KINOME<i>scan</i> services provided by DiscoveRx (no ATP used according to the protocol).</div></div><div id="sec4_5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Cell Lines and Cell Culture Conditions</h3><div class="NLM_p last">Cell lines were acquired from the American Type Culture Collection (Manassas, VA, USA) except those specifically mentioned. All cell lines were cultured in the designated medium containing 10% FBS (v/v) at 37 °C in a humidified 5% CO<sub>2</sub> incubator and passaged for <6 months after receipt or resuscitation.</div></div><div id="sec4_5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Cell Viability Assays</h3><div class="NLM_p last">The viability of cells was determined using the MTT assay method. The cell lines were seeded (2000–20000 cells per well, depending on the cell type) in 96-well plates. After incubation for 24 h in serum-containing media, the cells were treated with inhibitors (0–10 μg/mL) diluted with culture medium for 72 h at 37 °C under a 5% CO<sub>2</sub> atmosphere. Thereafter, 20 μL of the MTT reagent (5 mg/mL) was added to each well, and the plates were incubated for 2–4 h at 37 °C. For the adherent cells, the media and MTT were carefully aspirated from each well, and the formazan crystals were dissolved in 150 μL of DMSO. For the suspended cells, 50 μL of 20% acidified SDS (w/v) was added to each well, and the cells were incubated overnight. Finally, the absorbance at 570 nm was read using a Multiskan MK3 ELISA photometer (Thermo Scientific). All experiments were performed in triplicate.</div></div><div id="sec4_5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Western Blot Assays</h3><div class="NLM_p last">The HCC827 immunoblot studied cells treated with either compound <b>9e</b> or gefitinib (0–1 μmol/L) for 8 h. Whole-cell protein lysates were prepared and centrifuged for 15 min at 13000 rpm and 4 °C to remove any insoluble material. The total proteins were determined using the Bradford method, and an equivalent quantity of protein was combined with an SDS-PAGE loading buffer (Beyotime) according to the manufacturer’s instructions. Proteins were separated via gel electrophoresis on 5–10% polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Millipore). Antibody–antigen complexes were detected using an enhanced chemiluminescence system (Millipore). The following antibodies from Cell Signaling Technology were used at a 1:1000 dilution: anti-EGFR, anti-pEGFRTyr1068, anti-AKT, anti-pAKTSer473, anti-ERK, and anti-pERKThr202/Tyr204. The anti-β-actin primary antibody was used at a 1:2000 dilution, and the horseradish peroxidase-coupled secondary antibodies were used at a 1:5000 dilution. For the H1975 Western blot assay, cells were incubated overnight in serum-free media. Compound <b>9e</b> and gefitinib (0–10 μmol/L) were then added. After 3 h, the cells were stimulated with 100 ng/mL human recombinant EGF (Sigma) for 15 min. Western blots were performed on whole-cell extracts as described above.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> Immunohistochemistry</h3><div class="NLM_p last">Tumor-bearing female BALB/c mice were given compound <b>9e</b> (1 or 50 mg/kg) and a vehicle once daily via oral gavage, and the tumors were harvested 3 or 10 days later. The tumors were fixed with formalin and embedded in paraffin. For immunohistochemistry staining, antigen retrieval was performed on paraffin-embedded tumor sections and the following primary antibodies were used: phospho-EGFR (Cell Signaling Technology, 1:100) and Ki67 (Thermo Fisher Scientific, 1:100). A polymer detection system (Dako EnVision+ K4007) was used for secondary detection, and the sections were counterstained with Carazzi’s hematoxylin. Images were captured using an Olympus digital camera attached to a light microscope.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Pharmacokinetic Assessments</h3><div class="NLM_p">Catheters were surgically placed into the femoral veins of male Sprague–Dawley rats (HFK Biotechnology, Beijing, China) to collect serial blood samples. The animals were fasted overnight prior to dosing, and food was withheld until 4 h after dosing. Compound <b>9e</b> was formulated for oral administration in 5% DMSO/15% PEG/80% sterile water at a target concentration of 4 mg/mL. The mice (220–250 g) were administered a single dose of 20 mg/kg compound <b>9e</b> via oral gavage. Blood was collected in heparin-containing tubes, and the plasma was isolated by centrifugation. The plasma concentrations of compound <b>9e</b> were determined using liquid–liquid extraction followed by high-performance liquid chromatography (HPLC) with tandem mass spectrometric detection (3200 QTRAP system; Applied Biosystems). Noncompartmental pharmacokinetic parameters were obtained from the plasma concentration–time profiles using DAS software (Enterprise version 2.0; Mathematical Pharmacology Professional Committee of China).</div><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Xenograft Models</h4><div class="NLM_p last">All animal experiments were approved by the Animal Care and Use Committee of Sichuan University. Cells were harvested during the exponential growth phase, washed three times with serum-free medium, and resuspended at a concentration of 5 × 10<sup>7</sup>–1 × 10<sup>8</sup> cells/mL. Tumor xenograft models were established by subcutaneously injecting 100 μL of tumor cell suspension into the right flank of female BALB/c nude mice (6–8 weeks old). The mice were randomized into four or five groups (six mice per group) prior to treatment with compound <b>9e</b>, gefitinib, or BIBW2992. The animals were given compound <b>9e</b> (1–50 mg/kg), gefitinib (100 mg/kg), BIBW2992 (20 mg/kg), or vehicle alone (25% PEG400 plus 5% DMSO in sterile water) once daily via oral gavage. Tumors were measured twice weekly using calipers, and their volume was calculated using the following formula: tumor volume = <i>a</i> × <i>b</i><sup>2</sup> × 0.52 (<i>a</i> = long diameter; <i>b</i> = short diameter).</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> Molecular Docking Study</h3><div class="NLM_p">All molecular docking studies were carried out on GOLD (Genetic Optimization of Ligand Docking) 4.0.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> GOLD uses a genetic algorithm to dock flexible ligands into protein binding sites. The crystal structure (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>) of the kinase domain of EGFR (T790M) bound to the inhibitor compound AEE788 was used in the docking studies.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Hydrogen atoms were added to the protein using Accelrys Discovery Studio 2.55. The Charmm force field was assigned. The binding site was defined as a sphere containing the residues that remain within 10 Å of the ligand, an area large enough to cover the ATP-binding region at the active site.</div><div class="NLM_p last">In the process of hit discovery, molecular docking (GOLD) was performed against an in-house focused virtual library containing approximately 650 000 known kinase inhibitors and kinase inhibitor-like compounds; these compounds were selected in advance from several chemical libraries including BindingDB, ChemBl, Specs, and Enamine, as well as a database of chemicals synthesized by us. This focused virtual library contains all of the kinase inhibitors presented in BindingDB and ChemBl. The 3D conformations of compounds in virtual screening were generated by GOLD. The ID-Score scoring function proposed by us was calculated for ranking the screening compounds.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm301365e" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54032" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54032" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheng-Yong Yang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6019010e071319201303154e0504154e030e"><span class="__cf_email__" data-cfemail="4a332b242d39330a39293f642f2e3f642924">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiao Yang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span>; 
    <span class="hlFld-Affiliation affiliation">West China School
of Pharmacy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li-Jiao Wang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing-Jing Liu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Zhong</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ren-Lin Zheng</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Xu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pan Ji</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun-Hui Zhang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen-Jing Wang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xing-Dong Lin</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lin-Li Li</span> - <span class="hlFld-Affiliation affiliation">West China School
of Pharmacy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu-Quan Wei</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory
of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>These authors contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2402e4609-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (81172987), the 973 Program (2013CB967204), the National S&T Major Project (2012ZX09102-101-002), and the 863 Hi-Tech Program (2012AA020301, 2012AA020308).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i101" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i101"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i102" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i102"> Abbreviations Used</h2><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">DABCO</td><td class="NLM_def"><p class="first last">1,4-diaza[2.2.2]bicyclooctane</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naishadham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Cancer statistics</span> <span class="citation_source-journal">CA Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=10-29&author=R.+Siegelauthor=D.+Naishadhamauthor=A.+Jemal&title=Cancer+statistics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DNaishadham%26aufirst%3DD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%26jtitle%3DCA%2520Cancer%2520J.%2520Clin.%26date%3D2012%26volume%3D62%26spage%3D10%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spigel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCollum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzikansky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhlmann, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span> </span><span class="NLM_article-title">First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2442</span><span class="NLM_x">–</span> <span class="NLM_lpage">2449</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1200%2FJCO.2007.14.8494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=18458038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVKhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=2442-2449&author=L.+V.+Sequistauthor=R.+G.+Martinsauthor=D.+Spigelauthor=S.+M.+Grunbergauthor=A.+Spiraauthor=P.+A.+J%C3%A4nneauthor=V.+A.+Joshiauthor=D.+McCollumauthor=T.+L.+Evansauthor=A.+Muzikanskyauthor=G.+L.+Kuhlmannauthor=M.+Hanauthor=J.+S.+Goldbergauthor=J.+Settlemanauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=D.+A.+Haberauthor=B.+E.+Johnsonauthor=T.+J.+Lynch&title=First-line+gefitinib+in+patients+with+advanced+non-small-cell+lung+cancer+harboring+somatic+EGFR+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations</span></div><div class="casAuthors">Sequist, Lecia V.; Martins, Renato G.; Spigel, David; Grunberg, Steven M.; Spira, Alexander; Janne, Pasi A.; Joshi, Victoria A.; McCollum, David; Evans, Tracey L.; Muzikansky, Alona; Kuhlmann, Georgiana L.; Han, Moon; Goldberg, Jonathan S.; Settleman, Jeffrey; Iafrate, A. John; Engelman, Jeffrey A.; Haber, Daniel A.; Johnson, Bruce E.; Lynch, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2442-2449</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs).  The multicenter iTARGET trial prospectively examd. first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms.  Patients and Methods: Chemotherapy-naive patients with advanced NSCLC with ≥ 1 clin. characteristic assocd. with EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21.  Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity.  The primary outcome was response rate.  Results: Ninety-eight patients underwent EGFR screening and mutations were detected in 34 (35%).  EGFR mutations were primarily exon 19 deletions (53%) and L858R (26%) though 21 % of mutation-pos. cases had less common subtypes including exon 20 insertions, T790M/L858R, G719A, and L861Q.  Thirty-one patients received gefitinib.  The response rate was 55% (95% Cl, 33 to 70) and median progression-free survival was 9.2 mo (95% Cl, 6.2 to 11.8).  Therapy was well tolerated; 13% of patients had grade 3 toxicities including one grade 3 pneumonitis.  Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually assocd. with acquired TKI resistance, specifically the T790M EGFR mutation and MET amplification.  Conclusion: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clin. outcomes with good tolerance.  This strategy should be compared with combination chemotherapy, the current std. of care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiwzD0aI4fP7Vg90H21EOLACvtfcHk0livEAiUJ2bJZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVKhtbk%253D&md5=70e6f1208215e4f3ea141216cd80688d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.8494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.8494%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DMartins%26aufirst%3DR.%2BG.%26aulast%3DSpigel%26aufirst%3DD.%26aulast%3DGrunberg%26aufirst%3DS.%2BM.%26aulast%3DSpira%26aufirst%3DA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DJoshi%26aufirst%3DV.%2BA.%26aulast%3DMcCollum%26aufirst%3DD.%26aulast%3DEvans%26aufirst%3DT.%2BL.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DKuhlmann%26aufirst%3DG.%2BL.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DGoldberg%26aufirst%3DJ.%2BS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26atitle%3DFirst-line%2520gefitinib%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520harboring%2520somatic%2520EGFR%2520mutations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D2442%26epage%3D2449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0livEAiUJ2bJZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer.%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Johnson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobburu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chidambaram, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">6414</span><span class="NLM_x">–</span> <span class="NLM_lpage">6421</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1158%2F1078-0432.CCR-05-0790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=16166415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVShsLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=6414-6421&author=J.+R.+Johnsonauthor=M.+Cohenauthor=R.+Sridharaauthor=Y.+F.+Chenauthor=G.+M.+Williamsauthor=J.+Duanauthor=J.+Gobburuauthor=B.+Boothauthor=K.+Bensonauthor=J.+Leightonauthor=L.+S.+Hsiehauthor=N.+Chidambaramauthor=P.+Zimmermanauthor=R.+Pazdur&title=Approval+summary+for+erlotinib+for+treatment+of+patients+with+locally+advanced+or+metastatic+non-small+cell+lung+cancer+after+failure+of+at+least+one+prior+chemotherapy+regimen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen</span></div><div class="casAuthors">Johnson, John R.; Cohen, Martin; Sridhara, Rajeshwari; Chen, Yeh-Fong; Williams, Gene M.; Duan, John; Gobburu, Jogarao; Booth, Brian; Benson, Kimberly; Leighton, John; Hsieh, Li Shan; Chidambaram, Nallalerumal; Zimmerman, Paul; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6414-6421</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To describe the Food and Drug Administration (FDA) review and approval of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.  Exptl. Design: The FDA reviewed raw data in electronic format from a randomized controlled clin. trial comparing erlotinib with placebo in patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.  Results: Patients were randomized in a 2:1 ratio (erlotinib, n = 488 and placebo, n = 243).  Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.  Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.  Rash (75% vs. 17%) and diarrhea (54% vs. 18%) in the erlotinib and placebo group resp. were the most common adverse events.  Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.  Dose redns. were required for 10% of patients with rash and 4% of patients with diarrhea.  Conclusions: On Nov. 18, 2004, the FDA granted erlotinib regular approval for treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.  The applicant has committed to conduct post-marketing clin. trials to assess further the effect of epidermal growth factor receptor expression, measured with immunohistochem. staining, on erlotinib treatment effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Do8H4k6e7LVg90H21EOLACvtfcHk0ljftKBCbA4kTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVShsLfK&md5=7d27ecc72cbf8e5e063e93b12c4d98ce</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0790%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%2BF.%26aulast%3DWilliams%26aufirst%3DG.%2BM.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGobburu%26aufirst%3DJ.%26aulast%3DBooth%26aufirst%3DB.%26aulast%3DBenson%26aufirst%3DK.%26aulast%3DLeighton%26aufirst%3DJ.%26aulast%3DHsieh%26aufirst%3DL.%2BS.%26aulast%3DChidambaram%26aufirst%3DN.%26aulast%3DZimmerman%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%2520for%2520erlotinib%2520for%2520treatment%2520of%2520patients%2520with%2520locally%2520advanced%2520or%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%2520after%2520failure%2520of%2520at%2520least%2520one%2520prior%2520chemotherapy%2520regimen%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D6414%26epage%3D6421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Han, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. K.</span><span> </span><span class="NLM_article-title">Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2493</span><span class="NLM_x">–</span> <span class="NLM_lpage">2501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1200%2FJCO.2005.01.388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=15710947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVyktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=2493-2501&author=S.+W.+Hanauthor=T.+Y.+Kimauthor=P.+G.+Hwangauthor=S.+Jeongauthor=J.+Kimauthor=I.+S.+Choiauthor=D.+Y.+Ohauthor=J.+H.+Kimauthor=D.+W.+Kimauthor=D.+H.+Chungauthor=S.+A.+Imauthor=Y.+T.+Kimauthor=J.+S.+Leeauthor=D.+S.+Heoauthor=Y.+J.+Bangauthor=N.+K.+Kim&title=Predictive+and+prognostic+impact+of+epidermal+growth+factor+receptor+mutation+in+non-small-cell+lung+cancer+patients+treated+with+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib</span></div><div class="casAuthors">Han, Sae-Won; Kim, Tae-You; Hwang, Pil Gyu; Jeong, Soohyun; Kim, Jeongmi; Choi, In Sil; Oh, Do-Youn; Kim, Jee Hyun; Kim, Dong-Wan; Chung, Doo Hyun; Im, Seock-Ah; Kim, Young Tae; Lee, Jong Seok; Heo, Dae Seog; Bang, Yung-Jue; Kim, Noe Kyeong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2493-2501</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">This study was undertaken to investigate the effects of epidermal growth factor receptor (EGFR) mutation and its downstream signaling on response and survival in non-small-cell lung cancer (NSCLC) patients treated with gefitinib.  For 90 consecutive NSCLC patients who had received gefitinib, EGFR mutation was analyzed by DNA sequencing of exons 18, 19, 21, and 23 in the EGFR tyrosine kinase domain.  Expressions of phosphorylated (p) -Akt and p-Erk were detd. via immunohistochem.  Response rate, time to progression (TTP), and overall survival were compared between each group according to EGFR mutation, as well as p-Akt and p-Erk expression.  Seventeen patients (18.9%; 95% CI, 10.8 to 27.0) harbored EGFR mutations.  These mutations include deletions in exon 19 in seven patients, L858R in six patients, G719A in three, patients, and a novel A859T in one patient.  Response rate in patients with EGFR mutation was 64.7% (11 of 17 patients; 95% CI, 42.0 to 87.4), in contrast to 13.7% (10 of 73 patients; 95% CI, 5.8 to 21.6) in patients without mutation (P< .001).  Moreover, these 17 patients with EGFR mutation had significantly prolonged TTP (21.7 v 1.8 mo; P < .001) and overall survival (30.5 v 6.6 mo; P < .001) compared with the remaining 73 patients without mutation.  Although no significant correlation was detected between EGFR mutation and expressions of p-Akt or p-Erk, p-Akt overexpression was assocd. with prolonged TTP in patients with EGFR mutation.  Our data further support the importance of EGFR mutation with regard to gefitinib sensitivity.  In addn. to its predictive role, EGFR mutation confers significant survival benefits on NSCLC patients treated with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGgMZJcLgQubVg90H21EOLACvtfcHk0ljftKBCbA4kTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVyktL0%253D&md5=7dc1327ac74ca646f8d7f6cdbd61c270</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.388%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DHwang%26aufirst%3DP.%2BG.%26aulast%3DJeong%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DI.%2BS.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DChung%26aufirst%3DD.%2BH.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DKim%26aufirst%3DY.%2BT.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DN.%2BK.%26atitle%3DPredictive%2520and%2520prognostic%2520impact%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520mutation%2520in%2520non-small-cell%2520lung%2520cancer%2520patients%2520treated%2520with%2520gefitinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D2493%26epage%3D2501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zappaterra, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulmer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e313&author=H.+Greulichauthor=T.+H.+Chenauthor=W.+Fengauthor=P.+A.+J%C3%A4nneauthor=J.+V.+Alvarezauthor=M.+Zappaterraauthor=S.+E.+Bulmerauthor=D.+A.+Frankauthor=W.+C.+Hahnauthor=W.+R.+Sellersauthor=M.+Meyerson&title=Oncogenic+transformation+by+inhibitor-sensitive+and+-resistant+EGFR+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DAlvarez%26aufirst%3DJ.%2BV.%26aulast%3DZappaterra%26aufirst%3DM.%26aulast%3DBulmer%26aufirst%3DS.%2BE.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DOncogenic%2520transformation%2520by%2520inhibitor-sensitive%2520and%2520-resistant%2520EGFR%2520mutants%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Ciaardiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">EGFR antagonists in cancer treatment</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1160</span><span class="NLM_x">–</span> <span class="NLM_lpage">1174</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1056%2FNEJMra0707704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=18337605" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1160-1174&author=F.+Ciaardielloauthor=G.+Tortora&title=EGFR+antagonists+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0707704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0707704%26sid%3Dliteratum%253Aachs%26aulast%3DCiaardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR%2520antagonists%2520in%2520cancer%2520treatment%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1160%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">–</span> <span class="NLM_lpage">1167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+antiapoptotic+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520antiapoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Mok, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunpaweravong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margono, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiwaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chewaskulyong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffield, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span> </span><span class="NLM_article-title">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">957</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1056%2FNEJMoa0810699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=19692680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=947-957&author=T.+S.+Mokauthor=Y.+L.+Wuauthor=S.+Thongprasertauthor=C.+H.+Yangauthor=D.+T.+Chuauthor=N.+Saijoauthor=P.+Sunpaweravongauthor=B.+Hanauthor=B.+Margonoauthor=Y.+Ichinoseauthor=Y.+Nishiwakiauthor=Y.+Oheauthor=J.+J.+Yangauthor=B.+Chewaskulyongauthor=H.+Jiangauthor=E.+L.+Duffieldauthor=C.+L.+Watkinsauthor=A.+A.+Armourauthor=M.+Fukuoka&title=Gefitinib+or+carboplatin-paclitaxel+in+pulmonary+adenocarcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span></div><div class="casAuthors">Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.  METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calcd. to produce an area under the curve of 5 or 6 mg per mL per min) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients).  The primary end point was progression-free survival.  RESULTS: The 12-mo rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel.  The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P < 0.001).  In the subgroup of 261 patients who were pos. for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P < 0.001), whereas in the subgroup of 176 patients who were neg. for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P < 0.001).  The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group.  CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia.  The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKhpFOiEQu7Vg90H21EOLACvtfcHk0lhn3a4-BXJd-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK&md5=31ce0983eedb9f248dcf0726adf18b88</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810699%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DChu%26aufirst%3DD.%2BT.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DSunpaweravong%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DMargono%26aufirst%3DB.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DArmour%26aufirst%3DA.%2BA.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520or%2520carboplatin-paclitaxel%2520in%2520pulmonary%2520adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D947%26epage%3D957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lhn3a4-BXJd-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljy2oFjf36aMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span> </span><span class="NLM_article-title">Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1804</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1804&publication_year=2010&pages=559-566&author=M.+J.+Eckauthor=C.+H.+Yun&title=Structural+and+mechanistic+underpinnings+of+the+differential+drug+sensitivity+of+EGFR+mutations+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DStructural%2520and%2520mechanistic%2520underpinnings%2520of%2520the%2520differential%2520drug%2520sensitivity%2520of%2520EGFR%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2010%26volume%3D1804%26spage%3D559%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Mishani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abourbeh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dissoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben Daniel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5337</span><span class="NLM_x">–</span> <span class="NLM_lpage">5348</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0580196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5337-5348&author=E.+Mishaniauthor=G.+Abourbehauthor=O.+Jacobsonauthor=S.+Dissokiauthor=R.+Ben+Danielauthor=Y.+Rozenauthor=M.+Shaulauthor=A.+Levitzki&title=High-affinity+epidermal+growth+factor+receptor+%28EGFR%29+irreversible+inhibitors+with+diminished+chemical+reactivities+as+positron+emission+tomography+%28PET%29-imaging+agent+candidates+of+EGFR+overexpressing+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm0580196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0580196%26sid%3Dliteratum%253Aachs%26aulast%3DMishani%26aufirst%3DE.%26aulast%3DAbourbeh%26aufirst%3DG.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DDissoki%26aufirst%3DS.%26aulast%3DBen%2BDaniel%26aufirst%3DR.%26aulast%3DRozen%26aufirst%3DY.%26aulast%3DShaul%26aufirst%3DM.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DHigh-affinity%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520irreversible%2520inhibitors%2520with%2520diminished%2520chemical%2520reactivities%2520as%2520positron%2520emission%2520tomography%2520%2528PET%2529-imaging%2520agent%2520candidates%2520of%2520EGFR%2520overexpressing%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5337%26epage%3D5348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine<sup>790</sup> → methionine<sup>790</sup> mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%E2%86%92+methionine790+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Zhou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+J.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0ljBbQematYOQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%2BJ.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch., T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=H.+N.+Godinauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynch.author=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin%26aufirst%3DH.%2BN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch.%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Belani, C. P.</span><span> </span><span class="NLM_article-title">The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=413-423&author=C.+P.+Belani&title=The+role+of+irreversible+EGFR+inhibitors+in+the+treatment+of+non-small+cell+lung+cancer%3A+overcoming+resistance+to+reversible+EGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBelani%26aufirst%3DC.%2BP.%26atitle%3DThe%2520role%2520of%2520irreversible%2520EGFR%2520inhibitors%2520in%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%253A%2520overcoming%2520resistance%2520to%2520reversible%2520EGFR%2520inhibitors%26jtitle%3DCancer%2520Invest.%26date%3D2010%26volume%3D28%26spage%3D413%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">HKI-272 in non small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4593</span><span class="NLM_x">–</span> <span class="NLM_lpage">4596</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1158%2F1078-0432.CCR-07-0369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=17671147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlKjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4593-4596&author=K.+K.+Wong&title=HKI-272+in+non+small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">HKI-272 in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15, Pt. 2</span>),
    <span class="NLM_cas:pages">4593s-4596s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Somatic mutations in the kinase domain of the epidermal growth factor receptor (EGFR) gene are found in ∼10% of lung adenocarcinomas sequenced in the United States and in ∼30% sequenced in Asia.  These mutations are assocd. with sensitivity to the EGFR inhibitors gefitinib and erlotinib.  Many patients who initially respond to erlotinib or gefitinib subsequently relapse.  Studies have identified EGFR T790M mutations in tumors from patients who initially responded and then relapsed.  The T790M mutation, when combined in vitro with treatment-sensitizing EGFR mutations, permits the continued growth of tumor cells in the presence of erlotinib and gefitinib.  HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790M mutant cells in vitro in human lung cancer cell lines and in murine cells transfected with sensitizing EGFR mutations.  A phase I HKI-272 monotherapy trial in patients with solid tumors is close to completion.  Preliminary analyses of the trial, presented at the 2006 annual meeting of American Society of Clin. Oncol., showed that HKI-272 can achieve stable disease control for over 6 mo in some patients with non-small cell lung cancer that has progressed after treatment with gefitinib or erlotinib.  A phase II trial of HKI-272 in non-small cell lung cancer patients has been initiated.  HKI-272 might offer benefits to non-small cell lung cancer patients who have relapsed after an initial response to erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk5KWthnzz7LVg90H21EOLACvtfcHk0ljBbQematYOQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlKjsrw%253D&md5=24d09e44614f8286aa7b590ee86320e0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0369%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DHKI-272%2520in%2520non%2520small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4593%26epage%3D4596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amorusi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2252</span><span class="NLM_x">–</span> <span class="NLM_lpage">2260</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1200%2FJCO.2005.01.8960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=16710023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvV2ksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2252-2260&author=C.+Erlichmanauthor=M.+Hidalgoauthor=J.+P.+Boniauthor=P.+Martinsauthor=S.+E.+Quinnauthor=C.+Zacharchukauthor=P.+Amorusiauthor=A.+A.+Adjeiauthor=E.+K.+Rowinsky&title=Phase+I+study+of+EKB-569%2C+an+irreversible+inhibitor+of+the+epidermal+growth+factor+receptor%2C+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors</span></div><div class="casAuthors">Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P.; Martins, Patricia; Quinn, Susan E.; Zacharchuk, Charles; Amorusi, Peter; Adjei, Alex A.; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2252-2260</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The max. tolerated dose (MTD) and the dose-limiting toxicities of EKB-569, a selective, irreversible inhibitor of the epidermal growth factor receptor (EGFR), when administered orally once daily on an intermittent-dose schedule (14 days of a 28-day cycle) or on a continuous-dose schedule (each day of a 28-day cycle), were detd. in patients with advanced solid tumors.  Planned dose escalation was 25, 50, 75, 125, 175, and 225 mg.  Pharmacokinetic sampling was performed on days 1 and 14 for the intermittent-dose cohort and on days 1 and 15 for the continuous-dose cohort.  Thirty patients received a median of two cycles (range, one to 10 cycles) in the intermittent-dose cohort; 29 patients received a median of three cycles (range, one to eight cycles) in the continuous-dose cohort.  Dose-limiting toxicity was grade 3 diarrhea, and the MTD was 75 mg EKB-569 per day for both cohorts.  Other common toxicities included rash, nausea, and asthenia.  Exposure to EKB-569 was dose proportional.  At the MTD, the mean ± std. deviation terminal half-life was 21.7 ± 4.2 h and peak concn. increased 1.2-fold from day 1 to day 14/15.  No major antitumor responses were obsd.  However, one patient with non-small-cell lung cancer and one with cutaneous squamous cell carcinoma had stable disease for 33 and 24 wk, resp.  The MTD of once-daily oral EKB-569 is 75 mg.  The tolerable toxicity profile and long half-life of this irreversible EGFR inhibitor warrant its further evaluation as a single agent and in combination with other drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoWU_wd20ORbVg90H21EOLACvtfcHk0lgfEzvZ3JYeSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvV2ksLk%253D&md5=3a7766538e63808314fe4ea73b5f766d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.8960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.8960%26sid%3Dliteratum%253Aachs%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DBoni%26aufirst%3DJ.%2BP.%26aulast%3DMartins%26aufirst%3DP.%26aulast%3DQuinn%26aufirst%3DS.%2BE.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DAmorusi%26aufirst%3DP.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DPhase%2520I%2520study%2520of%2520EKB-569%252C%2520an%2520irreversible%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D2252%26epage%3D2260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an irreversible Pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=F.+Zejnullahuauthor=C.+M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.+K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+Pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DF.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520Pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.+H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+Inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0li8K1miU5DZJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520Inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abolhoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span> </span><span class="NLM_article-title">The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">–</span> <span class="NLM_lpage">791</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1158%2F1535-7163.MCT-11-0750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=22228822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=784-791&author=Y.+Kimauthor=J.+Koauthor=Z.+Cuiauthor=A.+Abolhodaauthor=J.+S.+Ahnauthor=S.+H.+Ouauthor=M.+J.+Ahnauthor=K.+Park&title=The+EGFR+T790M+mutation+in+acquired+resistance+to+an+irreversible+second-generation+EGFR+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor</span></div><div class="casAuthors">Kim, Youngwook; Ko, Jeonghun; Cui, ZhengYun; Abolhoda, Amir; Ahn, Jin Seok; Ou, Sai-Hong; Ahn, Myung-Ju; Park, Keunchil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-791</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR.  However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors.  Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear.  Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line.  Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clin. case.  The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiol. prevent the emergence of cells that are still dependent on EGFR signaling.  This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs.  Mol Cancer Ther; 11(3); 784-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhUxzW64OFLVg90H21EOLACvtfcHk0li8K1miU5DZJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D&md5=3cd09bb1dd73f8045b93b054c79480d3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0750%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DAbolhoda%26aufirst%3DA.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DPark%26aufirst%3DK.%26atitle%3DThe%2520EGFR%2520T790M%2520mutation%2520in%2520acquired%2520resistance%2520to%2520an%2520irreversible%2520second-generation%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D784%26epage%3D791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonesaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwiatkowski, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2346</span><span class="NLM_x">–</span> <span class="NLM_lpage">2356</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=2346-2356&author=D.+Ercanauthor=K.+Zejnullahuauthor=K.+Yonesakaauthor=Y.+Xiaoauthor=M.+Capellettiauthor=A.+Rogersauthor=E.+Lifshitsauthor=A.+Brownauthor=C.+Leeauthor=J.+G.+Christensenauthor=D.+J.+Kwiatkowskiauthor=J.+A.+Engelmanauthor=P.+A.+J%C3%A4nne&title=Amplification+of+EGFR+T790M+causes+resistance+to+an+irreversible+EGFR+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DYonesaka%26aufirst%3DK.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DRogers%26aufirst%3DA.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DAmplification%2520of%2520EGFR%2520T790M%2520causes%2520resistance%2520to%2520an%2520irreversible%2520EGFR%2520inhibitor%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D2346%26epage%3D2356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">952</span><span class="NLM_x">–</span> <span class="NLM_lpage">962</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1158%2F1535-7163.MCT-11-0679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=22319204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2nurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=952-962&author=Y.+Panauthor=Y.+Xuauthor=S.+Fengauthor=S.+Luoauthor=R.+Zhengauthor=J.+Yangauthor=L.+Wangauthor=L.+Zhongauthor=H.+Y.+Yangauthor=B.+L.+Wangauthor=Y.+Yuauthor=J.+Liuauthor=Z.+Caoauthor=X.+Wangauthor=P.+Jiauthor=Z.+Wangauthor=X.+Chenauthor=S.+Zhangauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=SKLB1206%2C+a+novel+orally+available+multikinase+inhibitor+targeting+EGFR+activating+and+T790M+mutants%2C+ErbB2%2C+ErbB4%2C+and+VEGFR2%2C+displays+potent+antitumor+activity+both+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo</span></div><div class="casAuthors">Pan, Youli; Xu, Yong; Feng, Shan; Luo, Shidong; Zheng, Renlin; Yang, Jiao; Wang, Lijiao; Zhong, Lei; Yang, Han-Yu; Wang, Bing-Lin; Yu, Yang; Liu, Jingjing; Cao, Zhixing; Wang, Xiaoyan; Ji, Pan; Wang, Zerong; Chen, Xin; Zhang, Shuang; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">952-962</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-epidermal growth factor receptor (EGFR) treatment has been successfully applied in clin. cancer therapy.  However, the clin. efficacy of first-generation reversible EGFR inhibitors, such as gefitinib and erlotinib, is limited by the development of drug-resistant mutations, including the gatekeeper T790M mutation and upregulation of alternative signaling pathways.  Second-generation irreversible EGFR inhibitors that were designed to overcome the drug resistance due to the T790M mutation have thus far had limited success.  Here, we report a novel reversible EGFR inhibitor, SKLB1206, which has potent activity against EGFR with gefitinib-sensitive and -resistant (T790M) mutations.  In addn., SKLB1206 has also considerable inhibition potency against some other related oncokinases, including ErbB2, ErbB4, and VEGF receptor 2 (VEGFR2).  SKLB1206 exhibited highly antiproliferative activity against a range of EGFR-mutant cell lines, including gefitinib-sensitive and -resistant cell lines, and EGFR or ErbB2-overexpressing cell lines.  SKLB1206 also showed a potent antiangiogenesis effect in vitro, in a zebrafish embryonic angiogenesis assay, and in an alginate-encapsulate tumor cell assay.  In vivo, oral administration of SKLB1206 showed complete tumor regression in gefitinib-sensitive HCC827 and PC-9 xenograft models and showed a considerable antitumor effect on the gefitinib-resistant H1975 model as well as other EGFR/ErbB2-overexpressing or -dependent tumor models including A431, LoVo, and N87 established in athymic mice.  SKLB1206 also showed a very good oral bioavailability (50.1%).  Collectively, these preclin. evaluations may support clin. development of SKLB1206 for cancers with EGFR-activating/resistance mutations or EGFR/ErbB2 overexpressed.  Mol Cancer Ther; 11(4); 952-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohH2DvdBSqXrVg90H21EOLACvtfcHk0lj5ae33RRoI1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2nurw%253D&md5=a920e9291f2fd615abb65de95f9a192a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0679%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DSKLB1206%252C%2520a%2520novel%2520orally%2520available%2520multikinase%2520inhibitor%2520targeting%2520EGFR%2520activating%2520and%2520T790M%2520mutants%252C%2520ErbB2%252C%2520ErbB4%252C%2520and%2520VEGFR2%252C%2520displays%2520potent%2520antitumor%2520activity%2520both%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D952%26epage%3D962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Antonello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarozzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morroni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrelia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, C.</span><span> </span><span class="NLM_article-title">Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6642</span><span class="NLM_x">–</span> <span class="NLM_lpage">6645</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0608762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6642-6645&author=A.+Antonelloauthor=A.+Tarozziauthor=F.+Morroniauthor=A.+Cavalliauthor=M.+Rosiniauthor=P.+Hreliaauthor=M.+L.+Bolognesiauthor=C.+Melchiorre&title=Multitarget-directed+drug+design+strategy%3A+a+novel+molecule+designed+to+block+epidermal+growth+factor+receptor+%28EGFR%29+and+to+exert+proapoptotic+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0608762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608762%26sid%3Dliteratum%253Aachs%26aulast%3DAntonello%26aufirst%3DA.%26aulast%3DTarozzi%26aufirst%3DA.%26aulast%3DMorroni%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DHrelia%26aufirst%3DP.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMultitarget-directed%2520drug%2520design%2520strategy%253A%2520a%2520novel%2520molecule%2520designed%2520to%2520block%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520to%2520exert%2520proapoptotic%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6642%26epage%3D6645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Wu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span> </span><span class="NLM_article-title">Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7316</span><span class="NLM_x">–</span> <span class="NLM_lpage">7326</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100607r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7316-7326&author=C.+H.+Wuauthor=M.+S.+Coumarauthor=C.+Y.+Chuauthor=W.+H.+Linauthor=Y.+R.+Chenauthor=C.+T.+Chenauthor=H.+Y.+Shiaoauthor=S.+Rafiauthor=S.+Y.+Wangauthor=H.+Hsuauthor=C.+H.+Chenauthor=C.+Y.+Changauthor=T.+Y.+Changauthor=T.+W.+Lienauthor=M.+Y.+Fangauthor=K.+C.+Yehauthor=C.+P.+Chenauthor=T.+K.+Yehauthor=S.+H.+Hsiehauthor=J.+T.+Hsuauthor=C.+C.+Liaoauthor=Y.+S.+Chaoauthor=H.+P.+Hsieh&title=Design+and+synthesis+of+tetrahydropyridothieno%5B2%2C3-d%5Dpyrimidine+scaffold+based+epidermal+growth+factor+receptor+%28EGFR%29+kinase+inhibitors%3A+the+role+of+side+chain+chirality+and+Michael+acceptor+group+for+maximal+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm100607r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100607r%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BR.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DShiao%26aufirst%3DH.%2BY.%26aulast%3DRafi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BY.%26aulast%3DHsu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DChang%26aufirst%3DT.%2BY.%26aulast%3DLien%26aufirst%3DT.%2BW.%26aulast%3DFang%26aufirst%3DM.%2BY.%26aulast%3DYeh%26aufirst%3DK.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DHsieh%26aufirst%3DS.%2BH.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DLiao%26aufirst%3DC.%2BC.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tetrahydropyridothieno%255B2%252C3-d%255Dpyrimidine%2520scaffold%2520based%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520kinase%2520inhibitors%253A%2520the%2520role%2520of%2520side%2520chain%2520chirality%2520and%2520Michael%2520acceptor%2520group%2520for%2520maximal%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7316%26epage%3D7326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oorui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8030</span><span class="NLM_x">–</span> <span class="NLM_lpage">8050</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2008634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8030-8050&author=T.+Ishikawaauthor=M.+Setoauthor=H.+Bannoauthor=Y.+Kawakitaauthor=M.+Ooruiauthor=T.+Taniguchiauthor=Y.+Ohtaauthor=T.+Tamuraauthor=A.+Nakayamaauthor=H.+Mikiauthor=H.+Kamiguchiauthor=T.+Tanakaauthor=N.+Habukaauthor=S.+Sogabeauthor=J.+Yanoauthor=K.+Aertgeertsauthor=K.+Kamiyama&title=Design+and+synthesis+of+novel+human+epidermal+growth+factor+receptor+2+%28HER2%29%2Fepidermal+growth+factor+receptor+%28EGFR%29+dual+inhibitors+bearing+a+pyrrolo%5B3%2C2-d%5Dpyrimidine+scaffold"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold</span></div><div class="casAuthors">Ishikawa, Tomoyasu; Seto, Masaki; Banno, Hiroshi; Kawakita, Youichi; Oorui, Mami; Taniguchi, Takahiko; Ohta, Yoshikazu; Tamura, Toshiya; Nakayama, Akiko; Miki, Hiroshi; Kamiguchi, Hidenori; Tanaka, Toshimasa; Habuka, Noriyuki; Sogabe, Satoshi; Yano, Jason; Aertgeerts, Kathleen; Kamiyama, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8030-8050</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer.  To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivs., e.g. I, capable of fitting into the receptors' ATP binding site.  Among the prepd. compds., I showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity.  The X-ray cocrystal structures of I with both HER2 and EGFR demonstrated that I interacts with the expected residues in their resp. ATP pockets.  Furthermore, reflecting its good oral bioavailability, I exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models.  On the basis of these findings, we report I (TAK-285) as a promising candidate for clin. development as a novel HER2/EGFR dual kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9QtqAj6idYrVg90H21EOLACvtfcHk0lgipVTMpbLl2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M&md5=ce030ac133a1c0ff7cb78b269ff85987</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm2008634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2008634%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DBanno%26aufirst%3DH.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DOorui%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DKamiyama%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252Fepidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520dual%2520inhibitors%2520bearing%2520a%2520pyrrolo%255B3%252C2-d%255Dpyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8030%26epage%3D8050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Jones, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glen, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span> </span><span class="NLM_article-title">Development and validation of a genetic algorithm for flexible docking</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1006%2Fjmbi.1996.0897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=9126849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1997&pages=727-748&author=G.+Jonesauthor=P.+Willettauthor=R.+C.+Glenauthor=A.+R.+Leachauthor=R.+Taylor&title=Development+and+validation+of+a+genetic+algorithm+for+flexible+docking"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a genetic algorithm for flexible docking</span></div><div class="casAuthors">Jones, Gareth; Willett, Peter; Glen, Robert C.; Leach, Andrew R.; Taylor, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">727-748</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Prediction of small mol. binding modes to macromols. of known three-dimensional structure is a problem of paramount importance in rational drug design (the "docking" problem).  We report the development and validation of the program GOLD (Genetic Optimization for Ligand Docking).  GOLD is an automated ligand docking program that uses a genetic algorithm to explore the full range of ligand conformational flexibility with partial flexibility of the protein and satisfies the fundamental requirement that the ligand must displace loosely bound water on binding.  Numerous enhancements and modifications have been applied to the original technique resulting in a substantial increase in the reliability and the applicability of the algorithm.  The advanced algorithm has been tested on a dataset of 100 complexes extd. from the Brookhaven Protein Data Bank.  When used to dock the ligand back into the binding site, GOLD achieved a 71% success rate in identifying the exptl. binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP3I60Rl2uorVg90H21EOLACvtfcHk0lgipVTMpbLl2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D&md5=476a2b1d8f80f3ba418052fe29d735ca</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1996.0897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1996.0897%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26aulast%3DWillett%26aufirst%3DP.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520genetic%2520algorithm%2520for%2520flexible%2520docking%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1997%26volume%3D267%26spage%3D727%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lgipVTMpbLl2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 32 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Douglas C.  Behenna</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Theodore O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">T. Eric  Ballard</span>, <span class="hlFld-ContribAuthor ">Louise  Bernier</span>, <span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle  Hemkens</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Manli  Shi</span>, <span class="hlFld-ContribAuthor ">James  Solowiej</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">Paolo  Vicini</span>, <span class="hlFld-ContribAuthor ">Yuli  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Longqing  Liu</span>, <span class="hlFld-ContribAuthor ">Yiqin  Luo</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Chengyi  Zhang</span>, and <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 3002-3019. <a href="https://doi.org/10.1021/acs.jmedchem.6b01894" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01894</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01894%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-%252528%2525283R%25252C4R%252529-4-Fluoro-1-%2525286-%252528%2525283-methoxy-1-methyl-1H-pyrazol-4-yl%252529amino%252529-9-methyl-9H-purin-2-yl%252529pyrrolidine-3-yl%252529acrylamide%252B%252528PF-06747775%252529%252Bthrough%252BStructure-Based%252BDrug%252BDesign%25253A%252BA%252BHigh%252BAffinity%252BIrreversible%252BInhibitor%252BTargeting%252BOncogenic%252BEGFR%252BMutants%252Bwith%252BSelectivity%252Bover%252BWild-Type%252BEGFR%26aulast%3DPlanken%26aufirst%3DSimon%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11012017%26date%3D29032017%26date%3D13042017%26date%3D13032017%26volume%3D60%26issue%3D7%26spage%3D3002%26epage%3D3019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6580-6594. <a href="https://doi.org/10.1021/acs.jmedchem.5b00840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChallenges%252Band%252BPerspectives%252Bon%252Bthe%252BDevelopment%252Bof%252BSmall-Molecule%252BEGFR%252BInhibitors%252Bagainst%252BT790M-Mediated%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D02062015%26date%3D26022016%26date%3D28072016%26date%3D16022016%26volume%3D59%26issue%3D14%26spage%3D6580%26epage%3D6594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mijoon  Lee</span>, <span class="hlFld-ContribAuthor ">Tomas  Rucil</span>, <span class="hlFld-ContribAuthor ">Dusan  Hesek</span>, <span class="hlFld-ContribAuthor ">Allen G.  Oliver</span>, <span class="hlFld-ContribAuthor ">Jed F.  Fisher</span>, and <span class="hlFld-ContribAuthor ">Shahriar  Mobashery</span>  . </span><span class="cited-content_cbyCitation_article-title">Regioselective Control of the SNAr Amination of 5-Substituted-2,4-Dichloropyrimidines Using Tertiary Amine Nucleophiles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2015,</strong> <em>80 </em>
                                    (15)
                                     , 7757-7763. <a href="https://doi.org/10.1021/acs.joc.5b01044" title="DOI URL">https://doi.org/10.1021/acs.joc.5b01044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.5b01044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.5b01044%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRegioselective%252BControl%252Bof%252Bthe%252BSNAr%252BAmination%252Bof%252B5-Substituted-2%25252C4-Dichloropyrimidines%252BUsing%252BTertiary%252BAmine%252BNucleophiles%26aulast%3DLee%26aufirst%3DMijoon%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D11052015%26date%3D17072015%26date%3D07082015%26date%3D08072015%26volume%3D80%26issue%3D15%26spage%3D7757%26epage%3D7763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>, and <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>  . </span><span class="cited-content_cbyCitation_article-title">Inhibitors of c-Jun N-Terminal Kinases: An Update. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (1)
                                     , 72-95. <a href="https://doi.org/10.1021/jm501212r" title="DOI URL">https://doi.org/10.1021/jm501212r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501212r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501212r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInhibitors%252Bof%252Bc-Jun%252BN-Terminal%252BKinases%25253A%252BAn%252BUpdate%26aulast%3DKoch%26aufirst%3DPierre%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D06082014%26date%3D08122014%26date%3D08012015%26date%3D21112014%26volume%3D58%26issue%3D1%26spage%3D72%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Scalvini</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Silvia  La Monica</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>190 </em>, 114643. <a href="https://doi.org/10.1016/j.bcp.2021.114643" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114643%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DFighting%252Btertiary%252Bmutations%252Bin%252BEGFR-driven%252Blung-cancers%25253A%252BCurrent%252Badvances%252Band%252Bfuture%252Bperspectives%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DScalvini%26aufirst%3DLaura%26date%3D2021%26volume%3D190%26spage%3D114643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rafael Augusto Alves  Ferreira</span>, <span class="hlFld-ContribAuthor ">Celso de Oliveira Rezende  Junior</span>, <span class="hlFld-ContribAuthor ">Pablo David Grigol  Martinez</span>, <span class="hlFld-ContribAuthor ">Paul John  Koovits</span>, <span class="hlFld-ContribAuthor ">Bruna Miranda  Soares</span>, <span class="hlFld-ContribAuthor ">Leonardo L. G.  Ferreira</span>, <span class="hlFld-ContribAuthor ">Simone  Michelan-Duarte</span>, <span class="hlFld-ContribAuthor ">Rafael Consolin  Chelucci</span>, <span class="hlFld-ContribAuthor ">Adriano D.  Andricopulo</span>, <span class="hlFld-ContribAuthor ">Mariana K.  Galuppo</span>, <span class="hlFld-ContribAuthor ">Silvia R. B.  Uliana</span>, <span class="hlFld-ContribAuthor ">An  Matheeussen</span>, <span class="hlFld-ContribAuthor ">Guy  Caljon</span>, <span class="hlFld-ContribAuthor ">Louis  Maes</span>, <span class="hlFld-ContribAuthor ">Simon  Campbell</span>, <span class="hlFld-ContribAuthor ">Jadel M.  Kratz</span>, <span class="hlFld-ContribAuthor ">Charles E.  Mowbray</span>, <span class="hlFld-ContribAuthor ">Luiz Carlos  Dias</span>, . </span><span class="cited-content_cbyCitation_article-title">2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling. </span><span class="cited-content_cbyCitation_journal-name">PLOS Neglected Tropical Diseases</span><span> <strong>2021,</strong> <em>15 </em>
                                    (2)
                                     , e0009196. <a href="https://doi.org/10.1371/journal.pntd.0009196" title="DOI URL">https://doi.org/10.1371/journal.pntd.0009196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pntd.0009196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pntd.0009196%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520Neglected%2520Tropical%2520Diseases%26atitle%3D2-aminobenzimidazoles%252Bfor%252Bleishmaniasis%25253A%252BFrom%252Binitial%252Bhit%252Bdiscovery%252Bto%252Bin%252Bvivo%252Bprofiling%26aulast%3DFerreira%26aufirst%3DRafael%2BAugusto%2BAlves%26date%3D2021%26date%3D2021%26volume%3D15%26issue%3D2%26spage%3De0009196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Xue-Yan  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Xiao-Xiao  Xi</span>, <span class="hlFld-ContribAuthor ">She-Min  Lu</span>, <span class="hlFld-ContribAuthor ">Jun-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent small molecule PROTACs targeting mutant EGFR. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112781. <a href="https://doi.org/10.1016/j.ejmech.2020.112781" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112781</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112781%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Bsmall%252Bmolecule%252BPROTACs%252Btargeting%252Bmutant%252BEGFR%26aulast%3DZhao%26aufirst%3DHong-Yi%26date%3D2020%26volume%3D208%26spage%3D112781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guo  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenqing  Zhang</span>, <span class="hlFld-ContribAuthor ">Chenjian  Shen</span>, <span class="hlFld-ContribAuthor ">Jinshan  Nan</span>, <span class="hlFld-ContribAuthor ">Ming  Chen</span>, <span class="hlFld-ContribAuthor ">Shusheng  Lai</span>, <span class="hlFld-ContribAuthor ">Jiemin  Zhong</span>, <span class="hlFld-ContribAuthor ">Bolin  Li</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Yifei  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Linli  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of small molecule FLT3 inhibitors that are able to overcome drug-resistant mutations. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (22)
                                     , 127532. <a href="https://doi.org/10.1016/j.bmcl.2020.127532" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127532</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127532%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bsmall%252Bmolecule%252BFLT3%252Binhibitors%252Bthat%252Bare%252Bable%252Bto%252Bovercome%252Bdrug-resistant%252Bmutations%26aulast%3DZhang%26aufirst%3DGuo%26date%3D2020%26volume%3D30%26issue%3D22%26spage%3D127532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Shu  Fan</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan-Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Jun-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">A-Qun  Zheng</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111888. <a href="https://doi.org/10.1016/j.ejmech.2019.111888" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111888</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111888%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B9-heterocyclyl%252Bsubstituted%252B9H-purines%252Bas%252BL858R%25252FT790M%25252FC797S%252Bmutant%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DLei%26aufirst%3DHao%26date%3D2020%26volume%3D186%26spage%3D111888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengxing  He</span>, <span class="hlFld-ContribAuthor ">Shenghui  Niu</span>, <span class="hlFld-ContribAuthor ">Shuai  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Shi</span>, <span class="hlFld-ContribAuthor ">Siqi  Feng</span>, <span class="hlFld-ContribAuthor ">Linna  Du</span>, <span class="hlFld-ContribAuthor ">Xuyang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhilu  Ma</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hongmin  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2019,</strong> <em>9 </em>
                                    (6)
                                     , 1193-1203. <a href="https://doi.org/10.1016/j.apsb.2019.06.010" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.06.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.06.010%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDiscovery%252Bof%252BWS-157%252Bas%252Ba%252Bhighly%252Bpotent%25252C%252Bselective%252Band%252Borally%252Bactive%252BEGFR%252Binhibitor%26aulast%3DHe%26aufirst%3DPengxing%26date%3D2019%26volume%3D9%26issue%3D6%26spage%3D1193%26epage%3D1203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Reversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 129-161. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00004-4" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00004-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00004-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00004-4%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BReversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D129%26epage%3D161%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (8)
                                     , 2173-2185. <a href="https://doi.org/10.1016/j.bmc.2018.03.025" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.03.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.03.025%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252B2%25252C9-disubstituted%252B8-phenylthio%25252Fphenylsulfinyl-9H-purine%252Bas%252Bnew%252BEGFR%252Binhibitors%26aulast%3DHei%26aufirst%3DYuan-Yuan%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D2173%26epage%3D2185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao-Qian  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan-Di  Zhao</span>, <span class="hlFld-ContribAuthor ">Xin-Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Bo  Wang</span>, <span class="hlFld-ContribAuthor ">Zhong-Hua  Li</span>, <span class="hlFld-ContribAuthor ">Zhang-Xu  He</span>, <span class="hlFld-ContribAuthor ">Xin-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian-Jia  Liang</span>, <span class="hlFld-ContribAuthor ">Li-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 6-chloro-2-(propylthio)-8,9-dihydro-7H-purines containing a carboxamide moiety as potential selective anti-lung cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 327-338. <a href="https://doi.org/10.1016/j.ejmech.2018.03.084" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.084%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B6-chloro-2-%252528propylthio%252529-8%25252C9-dihydro-7H-purines%252Bcontaining%252Ba%252Bcarboxamide%252Bmoiety%252Bas%252Bpotential%252Bselective%252Banti-lung%252Bcancer%252Bagents%26aulast%3DZhao%26aufirst%3DTao-Qian%26date%3D2018%26volume%3D151%26spage%3D327%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Su-Jie  Zhu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiao  Yang</span>, <span class="hlFld-ContribAuthor ">Rui  Ma</span>, <span class="hlFld-ContribAuthor ">Xiao-E  Yan</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>, <span class="hlFld-ContribAuthor ">Jing-Wen  Yang</span>, <span class="hlFld-ContribAuthor ">Cai-Hong  Yun</span>. </span><span class="cited-content_cbyCitation_article-title">Structural insights into drug development strategy targeting EGFR T790M/C797S. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (17)
                                     , 13652-13665. <a href="https://doi.org/10.18632/oncotarget.24113" title="DOI URL">https://doi.org/10.18632/oncotarget.24113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.24113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.24113%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DStructural%252Binsights%252Binto%252Bdrug%252Bdevelopment%252Bstrategy%252Btargeting%252BEGFR%252BT790M%25252FC797S%26aulast%3DZhu%26aufirst%3DSu-Jie%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D17%26spage%3D13652%26epage%3D13665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Duan</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 221-237. <a href="https://doi.org/10.1016/j.ejmech.2018.02.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4%25252C6-trisubstitued%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnew%252BEGFR-TKIs%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiao  Yang</span>, <span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Guo  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiu-Yuan  Yang</span>, <span class="hlFld-ContribAuthor ">Yue-Shan  Li</span>, <span class="hlFld-ContribAuthor ">Shen-Zhen  Huang</span>, <span class="hlFld-ContribAuthor ">Yan-Lin  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Xiao-Juan  Jiang</span>, <span class="hlFld-ContribAuthor ">Heng-Xiu  Yan</span>, <span class="hlFld-ContribAuthor ">Jing-Qiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">You-Fu  Luo</span>, <span class="hlFld-ContribAuthor ">Wei-Min  Li</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1148-1164. <a href="https://doi.org/10.1016/j.ejmech.2017.09.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Boptimization%252Band%252Bstructure-activity%252Brelationship%252Bstudies%252Bof%252BN-phenyl-7%25252C8-dihydro-6H-pyrimido%25255B5%25252C4-b%25255D%25255B1%25252C4%25255Doxazin-4-amine%252Bderivatives%252Bas%252Ba%252Bnew%252Bclass%252Bof%252Binhibitors%252Bof%252BRET%252Band%252Bits%252Bdrug%252Bresistance%252Bmutants%26aulast%3DYang%26aufirst%3DJiao%26date%3D2018%26volume%3D143%26spage%3D1148%26epage%3D1164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingfeng  Chen</span>, <span class="hlFld-ContribAuthor ">Weitao  Fu</span>, <span class="hlFld-ContribAuthor ">Chen  Feng</span>, <span class="hlFld-ContribAuthor ">Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lulu  Zheng</span>, <span class="hlFld-ContribAuthor ">Bo  Fang</span>, <span class="hlFld-ContribAuthor ">Yinda  Qiu</span>, <span class="hlFld-ContribAuthor ">Jie  Hu</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>, <span class="hlFld-ContribAuthor ">Jianpeng  Feng</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 510-527. <a href="https://doi.org/10.1016/j.ejmech.2017.08.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252B2%25252C4-diaminopyrimidines%252Bas%252BEGFR%252BL858R%25252FT790M%252Bselective%252Binhibitors%252Bfor%252BNSCLC%26aulast%3DChen%26aufirst%3DLingfeng%26date%3D2017%26volume%3D140%26spage%3D510%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Azim  Ansari</span>, <span class="hlFld-ContribAuthor ">Malleshappa  Noolvi</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (10)
                                     , 2713-2723. <a href="https://doi.org/10.1016/j.bmc.2017.03.039" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.03.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.03.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bquinazolinones%252Bas%252BEGFR%252Binhibitors%252Bto%252Bovercome%252BEGFR%252Bresistance%252Bobstacle%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2017%26volume%3D25%26issue%3D10%26spage%3D2713%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sen  Ji</span>, <span class="hlFld-ContribAuthor ">Shuang  Ma</span>, <span class="hlFld-ContribAuthor ">Wen-Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Shen-Zhen  Huang</span>, <span class="hlFld-ContribAuthor ">Tian-qi  Wang</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Yi-Guo  Hu</span>, <span class="hlFld-ContribAuthor ">Qiang  Chen</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2017,</strong> <em>89 </em>
                                    (4)
                                     , 585-598. <a href="https://doi.org/10.1111/cbdd.12881" title="DOI URL">https://doi.org/10.1111/cbdd.12881</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12881%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDiscovery%252Bof%252Bselective%252Bprotein%252Barginine%252Bmethyltransferase%252B5%252Binhibitors%252Band%252Bbiological%252Bevaluations%26aulast%3DJi%26aufirst%3DSen%26date%3D2017%26date%3D2016%26volume%3D89%26issue%3D4%26spage%3D585%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher  Deldaele</span>, <span class="hlFld-ContribAuthor ">Gwilherm  Evano</span>. </span><span class="cited-content_cbyCitation_article-title">Room-Temperature Practical Copper-Catalyzed Amination of Aryl Iodides. </span><span class="cited-content_cbyCitation_journal-name">ChemCatChem</span><span> <strong>2016,</strong> <em>8 </em>
                                    (7)
                                     , 1319-1328. <a href="https://doi.org/10.1002/cctc.201501375" title="DOI URL">https://doi.org/10.1002/cctc.201501375</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cctc.201501375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcctc.201501375%26sid%3Dliteratum%253Aachs%26jtitle%3DChemCatChem%26atitle%3DRoom-Temperature%252BPractical%252BCopper-Catalyzed%252BAmination%252Bof%252BAryl%252BIodides%26aulast%3DDeldaele%26aufirst%3DChristopher%26date%3D2016%26date%3D2016%26volume%3D8%26issue%3D7%26spage%3D1319%26epage%3D1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sahil  Sharma</span>, <span class="hlFld-ContribAuthor ">Jagjeet  Singh</span>, <span class="hlFld-ContribAuthor ">Ritu  Ojha</span>, <span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Manpreet  Kaur</span>, <span class="hlFld-ContribAuthor ">P.M.S.  Bedi</span>, <span class="hlFld-ContribAuthor ">Kunal  Nepali</span>. </span><span class="cited-content_cbyCitation_article-title">Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>112 </em>, 298-346. <a href="https://doi.org/10.1016/j.ejmech.2016.02.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.02.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.02.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bstrategies%25252C%252Bstructure%252Bactivity%252Brelationship%252Band%252Bmechanistic%252Binsights%252Bfor%252Bpurines%252Bas%252Bkinase%252Binhibitors%26aulast%3DSharma%26aufirst%3DSahil%26date%3D2016%26volume%3D112%26spage%3D298%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Lin  Hou</span>, <span class="hlFld-ContribAuthor ">Wenyan  Sun</span>, <span class="hlFld-ContribAuthor ">Zidong  Yu</span>, <span class="hlFld-ContribAuthor ">Jibo  Wang</span>, <span class="hlFld-ContribAuthor ">Hua  Gao</span>, <span class="hlFld-ContribAuthor ">Guiming  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of
              p
              -
              O
              -Alkyl Salicylanilide Derivatives as Novel EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Drug Development Research</span><span> <strong>2016,</strong> <em>77 </em>
                                    (1)
                                     , 37-42. <a href="https://doi.org/10.1002/ddr.21290" title="DOI URL">https://doi.org/10.1002/ddr.21290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ddr.21290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fddr.21290%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Development%2520Research%26atitle%3DSynthesis%252Bof%252Bp%252B-%252BO%252B-Alkyl%252BSalicylanilide%252BDerivatives%252Bas%252BNovel%252BEGFR%252BInhibitors%26aulast%3DZhang%26aufirst%3DLi%26date%3D2016%26date%3D2016%26volume%3D77%26issue%3D1%26spage%3D37%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chawannuch  Mudjupa</span>, <span class="hlFld-ContribAuthor ">Sherif  Abdelhamed</span>, <span class="hlFld-ContribAuthor ">Alaa  Refaat</span>, <span class="hlFld-ContribAuthor ">Satoru  Yokoyama</span>, <span class="hlFld-ContribAuthor ">Ikuo  Saiki</span>, <span class="hlFld-ContribAuthor ">Opa  Vajragupta</span>. </span><span class="cited-content_cbyCitation_article-title">Lead compound bearing caffeic scaffold induces EGFR suppression in solid tumor cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Applied Biomedicine</span><span> <strong>2015,</strong> <em>13 </em>
                                    (4)
                                     , 305-317. <a href="https://doi.org/10.1016/j.jab.2015.05.001" title="DOI URL">https://doi.org/10.1016/j.jab.2015.05.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jab.2015.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jab.2015.05.001%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Applied%2520Biomedicine%26atitle%3DLead%252Bcompound%252Bbearing%252Bcaffeic%252Bscaffold%252Binduces%252BEGFR%252Bsuppression%252Bin%252Bsolid%252Btumor%252Bcancer%252Bcells%26aulast%3DMudjupa%26aufirst%3DChawannuch%26date%3D2015%26volume%3D13%26issue%3D4%26spage%3D305%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Faqing  Ye</span>, <span class="hlFld-ContribAuthor ">Liangfang  Chen</span>, <span class="hlFld-ContribAuthor ">Lichuan  Hu</span>, <span class="hlFld-ContribAuthor ">Tong  Xiao</span>, <span class="hlFld-ContribAuthor ">Shufang  Yu</span>, <span class="hlFld-ContribAuthor ">Di  Chen</span>, <span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Sicen  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and preliminary biological evaluation of C-8 substituted guanine derivatives as small molecular inhibitors of FGFRs. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (7)
                                     , 1556-1560. <a href="https://doi.org/10.1016/j.bmcl.2015.02.010" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.02.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.02.010%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpreliminary%252Bbiological%252Bevaluation%252Bof%252BC-8%252Bsubstituted%252Bguanine%252Bderivatives%252Bas%252Bsmall%252Bmolecular%252Binhibitors%252Bof%252BFGFRs%26aulast%3DYe%26aufirst%3DFaqing%26date%3D2015%26volume%3D25%26issue%3D7%26spage%3D1556%26epage%3D1560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youli  Pan</span>, <span class="hlFld-ContribAuthor ">Mingwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Jiao  Yang</span>, <span class="hlFld-ContribAuthor ">Shu  Zhou</span>, <span class="hlFld-ContribAuthor ">Ya  Qin</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Yuzong  Chen</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2015,</strong> <em>14 </em>
                                    (2)
                                     , 407-418. <a href="https://doi.org/10.1158/1535-7163.MCT-14-0485" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-14-0485</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-14-0485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-14-0485%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DA%252BPreclinical%252BEvaluation%252Bof%252BSKLB261%25252C%252Ba%252BMultikinase%252BInhibitor%252Bof%252BEGFR%25252FSrc%25252FVEGFR2%25252C%252Bas%252Ba%252BTherapeutic%252BAgent%252Bagainst%252BPancreatic%252BCancer%26aulast%3DPan%26aufirst%3DYouli%26date%3D2015%26date%3D2014%26volume%3D14%26issue%3D2%26spage%3D407%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaoying  Tan</span>, <span class="hlFld-ContribAuthor ">Kun  Han</span>, <span class="hlFld-ContribAuthor ">Qiang  Li</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Yiqi  Yang</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Xuhong  Qian</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Novel metal complexes of naphthalimide–cyclam conjugates as potential multi-target receptor tyrosine kinase (RTK) inhibitors: Synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>85 </em>, 207-214. <a href="https://doi.org/10.1016/j.ejmech.2014.07.068" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.07.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.07.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.07.068%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bmetal%252Bcomplexes%252Bof%252Bnaphthalimide%2525E2%252580%252593cyclam%252Bconjugates%252Bas%252Bpotential%252Bmulti-target%252Breceptor%252Btyrosine%252Bkinase%252B%252528RTK%252529%252Binhibitors%25253A%252BSynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DTan%26aufirst%3DShaoying%26date%3D2014%26volume%3D85%26spage%3D207%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helmout  Modjtahedi</span>, <span class="hlFld-ContribAuthor ">Byoung Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Martin C.  Michel</span>, <span class="hlFld-ContribAuthor ">Flavio  Solca</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. </span><span class="cited-content_cbyCitation_journal-name">Naunyn-Schmiedeberg's Archives of Pharmacology</span><span> <strong>2014,</strong> <em>387 </em>
                                    (6)
                                     , 505-521. <a href="https://doi.org/10.1007/s00210-014-0967-3" title="DOI URL">https://doi.org/10.1007/s00210-014-0967-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00210-014-0967-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00210-014-0967-3%26sid%3Dliteratum%253Aachs%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Archives%2520of%2520Pharmacology%26atitle%3DA%252Bcomprehensive%252Breview%252Bof%252Bthe%252Bpreclinical%252Befficacy%252Bprofile%252Bof%252Bthe%252BErbB%252Bfamily%252Bblocker%252Bafatinib%252Bin%252Bcancer%26aulast%3DModjtahedi%26aufirst%3DHelmout%26date%3D2014%26date%3D2014%26volume%3D387%26issue%3D6%26spage%3D505%26epage%3D521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao  Li</span>, <span class="hlFld-ContribAuthor ">Wenmin  Chen</span>, <span class="hlFld-ContribAuthor ">Ye  Tian</span>, <span class="hlFld-ContribAuthor ">Huiqing  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Jan  Balzarini</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>80 </em>, 112-121. <a href="https://doi.org/10.1016/j.ejmech.2014.04.036" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.04.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.04.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.04.036%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bdiarylpyrimidines%252Bas%252Bpotent%252BHIV%252BNNRTIs%252Bvia%252Ba%252Bstructure-guided%252Bcore-refining%252Bapproach%26aulast%3DLi%26aufirst%3DXiao%26date%3D2014%26volume%3D80%26spage%3D112%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xun  Ji</span>, <span class="hlFld-ContribAuthor ">Ting  Peng</span>, <span class="hlFld-ContribAuthor ">Xu  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (7)
                                     , 2366-2378. <a href="https://doi.org/10.1016/j.bmc.2014.01.035" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.01.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.01.035%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B6-alkenylamides%252Bsubstituted%252Bof%252B4-anilinothieno%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Birreversible%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%26aulast%3DJi%26aufirst%3DXun%26date%3D2014%26volume%3D22%26issue%3D7%26spage%3D2366%26epage%3D2378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Si-Ning  Li</span>, <span class="hlFld-ContribAuthor ">Huan-Qiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor inhibitors: a patent review (2010 – present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (3)
                                     , 309-321. <a href="https://doi.org/10.1517/13543776.2014.871527" title="DOI URL">https://doi.org/10.1517/13543776.2014.871527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.871527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.871527%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%252B%2525282010%252B%2525E2%252580%252593%252Bpresent%252529%26aulast%3DLi%26aufirst%3DSi-Ning%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D3%26spage%3D309%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanan  Georgey</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Cytotoxic Activity and 2D-QSAR Study of Some Imidazoquinazoline Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2014,</strong> <em>19 </em>
                                    (3)
                                     , 3777-3792. <a href="https://doi.org/10.3390/molecules19033777" title="DOI URL">https://doi.org/10.3390/molecules19033777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules19033777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules19033777%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%25252C%252BCytotoxic%252BActivity%252Band%252B2D-QSAR%252BStudy%252Bof%252BSome%252BImidazoquinazoline%252BDerivatives%26aulast%3DGeorgey%26aufirst%3DHanan%26date%3D2014%26date%3D2014%26volume%3D19%26issue%3D3%26spage%3D3777%26epage%3D3792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  Zhang</span>, <span class="hlFld-ContribAuthor ">Ting  Peng</span>, <span class="hlFld-ContribAuthor ">Xun  Ji</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Zeng  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Yungen  Xu</span>, <span class="hlFld-ContribAuthor ">Mengyuan  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (24)
                                     , 7988-7998. <a href="https://doi.org/10.1016/j.bmc.2013.09.049" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.09.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.09.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.09.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B4-anilinoquinazolines%252Bwith%252BC-6%252Burea-linked%252Bside%252Bchains%252Bas%252Binhibitors%252Bof%252Bthe%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%26aulast%3DZhang%26aufirst%3DXu%26date%3D2013%26volume%3D21%26issue%3D24%26spage%3D7988%26epage%3D7998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Structure of hit compound <b>1</b>. (B) Moieties in compound <b>1</b> targeted for modification in this study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 2,8-Dianilinopurine Derivatives <b>9a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) 1-methylpiperazine, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 6 h, 95%; (ii) H<sub>2</sub>, 10% Pd/C, EtOH, rt, 9 h, 90%; (iii) CH<sub>2</sub>Cl<sub>2</sub>, DIEA, amine, −60 °C to room temperature, 60–75%; (iv) <i>n</i>-butanol, 90 °C, 5 h, 76%; (v) H<sub>2</sub>, 10% Pd/C, MeOH, 50 °C, 6 h, 85%; (vi) CH<sub>2</sub>Cl<sub>2</sub>, DIEA, EDIC, isothiocyanatobenzene, reflux, 12 h, 35–60%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 2,8-Dianilino-9-cyclopentylpurine Derivatives <b>14a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) morpholine, 4-methylpiperidine, ethanolamine, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 6 h, 70–85%; (ii) H<sub>2</sub>, 10% Pd/C, EtOH, rt, 9 h, 90%; (iii) <i>n</i>-butanol, 90 °C, 5 h, 76%; (iv) H<sub>2</sub>, 10% Pd/C, MeOH, 50 °C, 6 h, 85%; (v) CH<sub>2</sub>Cl<sub>2</sub>, DIEA, EDIC, isothiocyanatobenzene, reflux, 12 h, 35–60%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 2,8-Dianilino-9-cyclopentylpurine Derivatives <b>18a</b>–<b>j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) EtOH, CS<sub>2</sub>, DABCO, rt, 12 h, 60%; (ii) CH<sub>2</sub>Cl<sub>2</sub>, triphosgene, 0 °C, 1 h, reflux, 4 h, 65%; (iii) CH<sub>2</sub>Cl<sub>2</sub>, DIEA, EDIC, reflux, 12 h, 35–60%.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Putative binding mode of compound <b>1</b> within the active pocket of the EGFR T790 M mutant (the EGFR T790 M structure was taken from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Hydrogen bonds are shown as black dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of EGFR autophosphorylation and inactivation of downstream signaling proteins in cell cultures by compound <b>9e</b>. (A) HCC827 cells were treated with compound <b>9e</b> or gefitinib for 8 h. The cells were lysed, and the proteins were assessed by Western blot assay. (B) Serum-starved H1975 cells were treated with compound <b>9e</b> or gefitinib for 3 h, followed by the addition of EGF (100 ng/mL) for 15 min. Protein extracts were then analyzed by Western blot assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/medium/jm-2012-01365e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo antitumor effects of compound <b>9e</b> and its action mechanism. (A) Tumor growth curves for the HCC827 xenograft model. (B) Tumor growth curves for the H1975 xenograft model. Animals were randomized into groups (<i>n</i> = 6–8/group) and administered compound <b>9e</b>, gefitinib, BIBW2992, or vehicle once daily at the indicated dose levels when tumors reached the determined size. In both models, the animal weight and tumor volume were monitored twice weekly. Points indicate mean tumor volume (mm<sup>3</sup>); bars indicate SD. (C, D) Histological and immunohistochemical analyses demonstrating the effects of compound <b>9e</b> on the inhibition of EGFR phosphorylation and cell proliferation (Ki67) in tumor tissues. (C) In the HCC827 model, a dose of 1 mg/kg/day of compound <b>9e</b> was administered. After treatment for 3 days, the tumors were collected and analyzed. (D) In the H1975 model, a dose of 50 mg/kg/day was administered, and the tumors were collected and analyzed after 10 days of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301365e&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naishadham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Cancer statistics</span> <span class="citation_source-journal">CA Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=10-29&author=R.+Siegelauthor=D.+Naishadhamauthor=A.+Jemal&title=Cancer+statistics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DNaishadham%26aufirst%3DD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%26jtitle%3DCA%2520Cancer%2520J.%2520Clin.%26date%3D2012%26volume%3D62%26spage%3D10%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spigel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCollum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzikansky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhlmann, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span> </span><span class="NLM_article-title">First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2442</span><span class="NLM_x">–</span> <span class="NLM_lpage">2449</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1200%2FJCO.2007.14.8494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=18458038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVKhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=2442-2449&author=L.+V.+Sequistauthor=R.+G.+Martinsauthor=D.+Spigelauthor=S.+M.+Grunbergauthor=A.+Spiraauthor=P.+A.+J%C3%A4nneauthor=V.+A.+Joshiauthor=D.+McCollumauthor=T.+L.+Evansauthor=A.+Muzikanskyauthor=G.+L.+Kuhlmannauthor=M.+Hanauthor=J.+S.+Goldbergauthor=J.+Settlemanauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=D.+A.+Haberauthor=B.+E.+Johnsonauthor=T.+J.+Lynch&title=First-line+gefitinib+in+patients+with+advanced+non-small-cell+lung+cancer+harboring+somatic+EGFR+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations</span></div><div class="casAuthors">Sequist, Lecia V.; Martins, Renato G.; Spigel, David; Grunberg, Steven M.; Spira, Alexander; Janne, Pasi A.; Joshi, Victoria A.; McCollum, David; Evans, Tracey L.; Muzikansky, Alona; Kuhlmann, Georgiana L.; Han, Moon; Goldberg, Jonathan S.; Settleman, Jeffrey; Iafrate, A. John; Engelman, Jeffrey A.; Haber, Daniel A.; Johnson, Bruce E.; Lynch, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2442-2449</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs).  The multicenter iTARGET trial prospectively examd. first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms.  Patients and Methods: Chemotherapy-naive patients with advanced NSCLC with ≥ 1 clin. characteristic assocd. with EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21.  Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity.  The primary outcome was response rate.  Results: Ninety-eight patients underwent EGFR screening and mutations were detected in 34 (35%).  EGFR mutations were primarily exon 19 deletions (53%) and L858R (26%) though 21 % of mutation-pos. cases had less common subtypes including exon 20 insertions, T790M/L858R, G719A, and L861Q.  Thirty-one patients received gefitinib.  The response rate was 55% (95% Cl, 33 to 70) and median progression-free survival was 9.2 mo (95% Cl, 6.2 to 11.8).  Therapy was well tolerated; 13% of patients had grade 3 toxicities including one grade 3 pneumonitis.  Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually assocd. with acquired TKI resistance, specifically the T790M EGFR mutation and MET amplification.  Conclusion: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clin. outcomes with good tolerance.  This strategy should be compared with combination chemotherapy, the current std. of care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiwzD0aI4fP7Vg90H21EOLACvtfcHk0liw3V5JWLkXLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVKhtbk%253D&md5=70e6f1208215e4f3ea141216cd80688d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.8494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.8494%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DMartins%26aufirst%3DR.%2BG.%26aulast%3DSpigel%26aufirst%3DD.%26aulast%3DGrunberg%26aufirst%3DS.%2BM.%26aulast%3DSpira%26aufirst%3DA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DJoshi%26aufirst%3DV.%2BA.%26aulast%3DMcCollum%26aufirst%3DD.%26aulast%3DEvans%26aufirst%3DT.%2BL.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DKuhlmann%26aufirst%3DG.%2BL.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DGoldberg%26aufirst%3DJ.%2BS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26atitle%3DFirst-line%2520gefitinib%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520harboring%2520somatic%2520EGFR%2520mutations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D2442%26epage%3D2449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0liw3V5JWLkXLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer.%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Johnson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobburu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chidambaram, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">6414</span><span class="NLM_x">–</span> <span class="NLM_lpage">6421</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1158%2F1078-0432.CCR-05-0790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=16166415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVShsLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=6414-6421&author=J.+R.+Johnsonauthor=M.+Cohenauthor=R.+Sridharaauthor=Y.+F.+Chenauthor=G.+M.+Williamsauthor=J.+Duanauthor=J.+Gobburuauthor=B.+Boothauthor=K.+Bensonauthor=J.+Leightonauthor=L.+S.+Hsiehauthor=N.+Chidambaramauthor=P.+Zimmermanauthor=R.+Pazdur&title=Approval+summary+for+erlotinib+for+treatment+of+patients+with+locally+advanced+or+metastatic+non-small+cell+lung+cancer+after+failure+of+at+least+one+prior+chemotherapy+regimen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen</span></div><div class="casAuthors">Johnson, John R.; Cohen, Martin; Sridhara, Rajeshwari; Chen, Yeh-Fong; Williams, Gene M.; Duan, John; Gobburu, Jogarao; Booth, Brian; Benson, Kimberly; Leighton, John; Hsieh, Li Shan; Chidambaram, Nallalerumal; Zimmerman, Paul; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6414-6421</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To describe the Food and Drug Administration (FDA) review and approval of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.  Exptl. Design: The FDA reviewed raw data in electronic format from a randomized controlled clin. trial comparing erlotinib with placebo in patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.  Results: Patients were randomized in a 2:1 ratio (erlotinib, n = 488 and placebo, n = 243).  Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.  Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.  Rash (75% vs. 17%) and diarrhea (54% vs. 18%) in the erlotinib and placebo group resp. were the most common adverse events.  Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.  Dose redns. were required for 10% of patients with rash and 4% of patients with diarrhea.  Conclusions: On Nov. 18, 2004, the FDA granted erlotinib regular approval for treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.  The applicant has committed to conduct post-marketing clin. trials to assess further the effect of epidermal growth factor receptor expression, measured with immunohistochem. staining, on erlotinib treatment effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Do8H4k6e7LVg90H21EOLACvtfcHk0liw3V5JWLkXLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVShsLfK&md5=7d27ecc72cbf8e5e063e93b12c4d98ce</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0790%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%2BF.%26aulast%3DWilliams%26aufirst%3DG.%2BM.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGobburu%26aufirst%3DJ.%26aulast%3DBooth%26aufirst%3DB.%26aulast%3DBenson%26aufirst%3DK.%26aulast%3DLeighton%26aufirst%3DJ.%26aulast%3DHsieh%26aufirst%3DL.%2BS.%26aulast%3DChidambaram%26aufirst%3DN.%26aulast%3DZimmerman%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%2520for%2520erlotinib%2520for%2520treatment%2520of%2520patients%2520with%2520locally%2520advanced%2520or%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%2520after%2520failure%2520of%2520at%2520least%2520one%2520prior%2520chemotherapy%2520regimen%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D6414%26epage%3D6421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Han, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. K.</span><span> </span><span class="NLM_article-title">Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2493</span><span class="NLM_x">–</span> <span class="NLM_lpage">2501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1200%2FJCO.2005.01.388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=15710947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVyktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=2493-2501&author=S.+W.+Hanauthor=T.+Y.+Kimauthor=P.+G.+Hwangauthor=S.+Jeongauthor=J.+Kimauthor=I.+S.+Choiauthor=D.+Y.+Ohauthor=J.+H.+Kimauthor=D.+W.+Kimauthor=D.+H.+Chungauthor=S.+A.+Imauthor=Y.+T.+Kimauthor=J.+S.+Leeauthor=D.+S.+Heoauthor=Y.+J.+Bangauthor=N.+K.+Kim&title=Predictive+and+prognostic+impact+of+epidermal+growth+factor+receptor+mutation+in+non-small-cell+lung+cancer+patients+treated+with+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib</span></div><div class="casAuthors">Han, Sae-Won; Kim, Tae-You; Hwang, Pil Gyu; Jeong, Soohyun; Kim, Jeongmi; Choi, In Sil; Oh, Do-Youn; Kim, Jee Hyun; Kim, Dong-Wan; Chung, Doo Hyun; Im, Seock-Ah; Kim, Young Tae; Lee, Jong Seok; Heo, Dae Seog; Bang, Yung-Jue; Kim, Noe Kyeong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2493-2501</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">This study was undertaken to investigate the effects of epidermal growth factor receptor (EGFR) mutation and its downstream signaling on response and survival in non-small-cell lung cancer (NSCLC) patients treated with gefitinib.  For 90 consecutive NSCLC patients who had received gefitinib, EGFR mutation was analyzed by DNA sequencing of exons 18, 19, 21, and 23 in the EGFR tyrosine kinase domain.  Expressions of phosphorylated (p) -Akt and p-Erk were detd. via immunohistochem.  Response rate, time to progression (TTP), and overall survival were compared between each group according to EGFR mutation, as well as p-Akt and p-Erk expression.  Seventeen patients (18.9%; 95% CI, 10.8 to 27.0) harbored EGFR mutations.  These mutations include deletions in exon 19 in seven patients, L858R in six patients, G719A in three, patients, and a novel A859T in one patient.  Response rate in patients with EGFR mutation was 64.7% (11 of 17 patients; 95% CI, 42.0 to 87.4), in contrast to 13.7% (10 of 73 patients; 95% CI, 5.8 to 21.6) in patients without mutation (P< .001).  Moreover, these 17 patients with EGFR mutation had significantly prolonged TTP (21.7 v 1.8 mo; P < .001) and overall survival (30.5 v 6.6 mo; P < .001) compared with the remaining 73 patients without mutation.  Although no significant correlation was detected between EGFR mutation and expressions of p-Akt or p-Erk, p-Akt overexpression was assocd. with prolonged TTP in patients with EGFR mutation.  Our data further support the importance of EGFR mutation with regard to gefitinib sensitivity.  In addn. to its predictive role, EGFR mutation confers significant survival benefits on NSCLC patients treated with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGgMZJcLgQubVg90H21EOLACvtfcHk0ljptjLfWomRLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVyktL0%253D&md5=7dc1327ac74ca646f8d7f6cdbd61c270</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.388%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DHwang%26aufirst%3DP.%2BG.%26aulast%3DJeong%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DI.%2BS.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DChung%26aufirst%3DD.%2BH.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DKim%26aufirst%3DY.%2BT.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DN.%2BK.%26atitle%3DPredictive%2520and%2520prognostic%2520impact%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520mutation%2520in%2520non-small-cell%2520lung%2520cancer%2520patients%2520treated%2520with%2520gefitinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D2493%26epage%3D2501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zappaterra, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulmer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e313&author=H.+Greulichauthor=T.+H.+Chenauthor=W.+Fengauthor=P.+A.+J%C3%A4nneauthor=J.+V.+Alvarezauthor=M.+Zappaterraauthor=S.+E.+Bulmerauthor=D.+A.+Frankauthor=W.+C.+Hahnauthor=W.+R.+Sellersauthor=M.+Meyerson&title=Oncogenic+transformation+by+inhibitor-sensitive+and+-resistant+EGFR+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DAlvarez%26aufirst%3DJ.%2BV.%26aulast%3DZappaterra%26aufirst%3DM.%26aulast%3DBulmer%26aufirst%3DS.%2BE.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DOncogenic%2520transformation%2520by%2520inhibitor-sensitive%2520and%2520-resistant%2520EGFR%2520mutants%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Ciaardiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">EGFR antagonists in cancer treatment</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1160</span><span class="NLM_x">–</span> <span class="NLM_lpage">1174</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1056%2FNEJMra0707704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=18337605" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1160-1174&author=F.+Ciaardielloauthor=G.+Tortora&title=EGFR+antagonists+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0707704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0707704%26sid%3Dliteratum%253Aachs%26aulast%3DCiaardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR%2520antagonists%2520in%2520cancer%2520treatment%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1160%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">–</span> <span class="NLM_lpage">1167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+antiapoptotic+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520antiapoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Mok, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunpaweravong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margono, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiwaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chewaskulyong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffield, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span> </span><span class="NLM_article-title">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">957</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1056%2FNEJMoa0810699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=19692680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=947-957&author=T.+S.+Mokauthor=Y.+L.+Wuauthor=S.+Thongprasertauthor=C.+H.+Yangauthor=D.+T.+Chuauthor=N.+Saijoauthor=P.+Sunpaweravongauthor=B.+Hanauthor=B.+Margonoauthor=Y.+Ichinoseauthor=Y.+Nishiwakiauthor=Y.+Oheauthor=J.+J.+Yangauthor=B.+Chewaskulyongauthor=H.+Jiangauthor=E.+L.+Duffieldauthor=C.+L.+Watkinsauthor=A.+A.+Armourauthor=M.+Fukuoka&title=Gefitinib+or+carboplatin-paclitaxel+in+pulmonary+adenocarcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span></div><div class="casAuthors">Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.  METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calcd. to produce an area under the curve of 5 or 6 mg per mL per min) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients).  The primary end point was progression-free survival.  RESULTS: The 12-mo rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel.  The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P < 0.001).  In the subgroup of 261 patients who were pos. for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P < 0.001), whereas in the subgroup of 176 patients who were neg. for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P < 0.001).  The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group.  CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia.  The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKhpFOiEQu7Vg90H21EOLACvtfcHk0ljptjLfWomRLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK&md5=31ce0983eedb9f248dcf0726adf18b88</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810699%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DChu%26aufirst%3DD.%2BT.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DSunpaweravong%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DMargono%26aufirst%3DB.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DArmour%26aufirst%3DA.%2BA.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520or%2520carboplatin-paclitaxel%2520in%2520pulmonary%2520adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D947%26epage%3D957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0li9BpBmM0AfDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0li9BpBmM0AfDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span> </span><span class="NLM_article-title">Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1804</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1804&publication_year=2010&pages=559-566&author=M.+J.+Eckauthor=C.+H.+Yun&title=Structural+and+mechanistic+underpinnings+of+the+differential+drug+sensitivity+of+EGFR+mutations+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DStructural%2520and%2520mechanistic%2520underpinnings%2520of%2520the%2520differential%2520drug%2520sensitivity%2520of%2520EGFR%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2010%26volume%3D1804%26spage%3D559%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Mishani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abourbeh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dissoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben Daniel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5337</span><span class="NLM_x">–</span> <span class="NLM_lpage">5348</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0580196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5337-5348&author=E.+Mishaniauthor=G.+Abourbehauthor=O.+Jacobsonauthor=S.+Dissokiauthor=R.+Ben+Danielauthor=Y.+Rozenauthor=M.+Shaulauthor=A.+Levitzki&title=High-affinity+epidermal+growth+factor+receptor+%28EGFR%29+irreversible+inhibitors+with+diminished+chemical+reactivities+as+positron+emission+tomography+%28PET%29-imaging+agent+candidates+of+EGFR+overexpressing+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm0580196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0580196%26sid%3Dliteratum%253Aachs%26aulast%3DMishani%26aufirst%3DE.%26aulast%3DAbourbeh%26aufirst%3DG.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DDissoki%26aufirst%3DS.%26aulast%3DBen%2BDaniel%26aufirst%3DR.%26aulast%3DRozen%26aufirst%3DY.%26aulast%3DShaul%26aufirst%3DM.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DHigh-affinity%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520irreversible%2520inhibitors%2520with%2520diminished%2520chemical%2520reactivities%2520as%2520positron%2520emission%2520tomography%2520%2528PET%2529-imaging%2520agent%2520candidates%2520of%2520EGFR%2520overexpressing%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5337%26epage%3D5348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine<sup>790</sup> → methionine<sup>790</sup> mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%E2%86%92+methionine790+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Zhou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+J.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0liO5H-5QtHlrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%2BJ.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch., T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=H.+N.+Godinauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynch.author=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin%26aufirst%3DH.%2BN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch.%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Belani, C. P.</span><span> </span><span class="NLM_article-title">The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=413-423&author=C.+P.+Belani&title=The+role+of+irreversible+EGFR+inhibitors+in+the+treatment+of+non-small+cell+lung+cancer%3A+overcoming+resistance+to+reversible+EGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBelani%26aufirst%3DC.%2BP.%26atitle%3DThe%2520role%2520of%2520irreversible%2520EGFR%2520inhibitors%2520in%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%253A%2520overcoming%2520resistance%2520to%2520reversible%2520EGFR%2520inhibitors%26jtitle%3DCancer%2520Invest.%26date%3D2010%26volume%3D28%26spage%3D413%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">HKI-272 in non small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4593</span><span class="NLM_x">–</span> <span class="NLM_lpage">4596</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1158%2F1078-0432.CCR-07-0369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=17671147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlKjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4593-4596&author=K.+K.+Wong&title=HKI-272+in+non+small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">HKI-272 in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15, Pt. 2</span>),
    <span class="NLM_cas:pages">4593s-4596s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Somatic mutations in the kinase domain of the epidermal growth factor receptor (EGFR) gene are found in ∼10% of lung adenocarcinomas sequenced in the United States and in ∼30% sequenced in Asia.  These mutations are assocd. with sensitivity to the EGFR inhibitors gefitinib and erlotinib.  Many patients who initially respond to erlotinib or gefitinib subsequently relapse.  Studies have identified EGFR T790M mutations in tumors from patients who initially responded and then relapsed.  The T790M mutation, when combined in vitro with treatment-sensitizing EGFR mutations, permits the continued growth of tumor cells in the presence of erlotinib and gefitinib.  HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790M mutant cells in vitro in human lung cancer cell lines and in murine cells transfected with sensitizing EGFR mutations.  A phase I HKI-272 monotherapy trial in patients with solid tumors is close to completion.  Preliminary analyses of the trial, presented at the 2006 annual meeting of American Society of Clin. Oncol., showed that HKI-272 can achieve stable disease control for over 6 mo in some patients with non-small cell lung cancer that has progressed after treatment with gefitinib or erlotinib.  A phase II trial of HKI-272 in non-small cell lung cancer patients has been initiated.  HKI-272 might offer benefits to non-small cell lung cancer patients who have relapsed after an initial response to erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk5KWthnzz7LVg90H21EOLACvtfcHk0lisJdrmrarT_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlKjsrw%253D&md5=24d09e44614f8286aa7b590ee86320e0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0369%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DHKI-272%2520in%2520non%2520small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4593%26epage%3D4596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amorusi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2252</span><span class="NLM_x">–</span> <span class="NLM_lpage">2260</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1200%2FJCO.2005.01.8960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=16710023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvV2ksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2252-2260&author=C.+Erlichmanauthor=M.+Hidalgoauthor=J.+P.+Boniauthor=P.+Martinsauthor=S.+E.+Quinnauthor=C.+Zacharchukauthor=P.+Amorusiauthor=A.+A.+Adjeiauthor=E.+K.+Rowinsky&title=Phase+I+study+of+EKB-569%2C+an+irreversible+inhibitor+of+the+epidermal+growth+factor+receptor%2C+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors</span></div><div class="casAuthors">Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P.; Martins, Patricia; Quinn, Susan E.; Zacharchuk, Charles; Amorusi, Peter; Adjei, Alex A.; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2252-2260</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The max. tolerated dose (MTD) and the dose-limiting toxicities of EKB-569, a selective, irreversible inhibitor of the epidermal growth factor receptor (EGFR), when administered orally once daily on an intermittent-dose schedule (14 days of a 28-day cycle) or on a continuous-dose schedule (each day of a 28-day cycle), were detd. in patients with advanced solid tumors.  Planned dose escalation was 25, 50, 75, 125, 175, and 225 mg.  Pharmacokinetic sampling was performed on days 1 and 14 for the intermittent-dose cohort and on days 1 and 15 for the continuous-dose cohort.  Thirty patients received a median of two cycles (range, one to 10 cycles) in the intermittent-dose cohort; 29 patients received a median of three cycles (range, one to eight cycles) in the continuous-dose cohort.  Dose-limiting toxicity was grade 3 diarrhea, and the MTD was 75 mg EKB-569 per day for both cohorts.  Other common toxicities included rash, nausea, and asthenia.  Exposure to EKB-569 was dose proportional.  At the MTD, the mean ± std. deviation terminal half-life was 21.7 ± 4.2 h and peak concn. increased 1.2-fold from day 1 to day 14/15.  No major antitumor responses were obsd.  However, one patient with non-small-cell lung cancer and one with cutaneous squamous cell carcinoma had stable disease for 33 and 24 wk, resp.  The MTD of once-daily oral EKB-569 is 75 mg.  The tolerable toxicity profile and long half-life of this irreversible EGFR inhibitor warrant its further evaluation as a single agent and in combination with other drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoWU_wd20ORbVg90H21EOLACvtfcHk0lisJdrmrarT_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvV2ksLk%253D&md5=3a7766538e63808314fe4ea73b5f766d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.8960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.8960%26sid%3Dliteratum%253Aachs%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DBoni%26aufirst%3DJ.%2BP.%26aulast%3DMartins%26aufirst%3DP.%26aulast%3DQuinn%26aufirst%3DS.%2BE.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DAmorusi%26aufirst%3DP.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DPhase%2520I%2520study%2520of%2520EKB-569%252C%2520an%2520irreversible%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D2252%26epage%3D2260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an irreversible Pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=F.+Zejnullahuauthor=C.+M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.+K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+Pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DF.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520Pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.+H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+Inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0liGdwtr5QQlsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520Inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abolhoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span> </span><span class="NLM_article-title">The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">–</span> <span class="NLM_lpage">791</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1158%2F1535-7163.MCT-11-0750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=22228822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=784-791&author=Y.+Kimauthor=J.+Koauthor=Z.+Cuiauthor=A.+Abolhodaauthor=J.+S.+Ahnauthor=S.+H.+Ouauthor=M.+J.+Ahnauthor=K.+Park&title=The+EGFR+T790M+mutation+in+acquired+resistance+to+an+irreversible+second-generation+EGFR+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor</span></div><div class="casAuthors">Kim, Youngwook; Ko, Jeonghun; Cui, ZhengYun; Abolhoda, Amir; Ahn, Jin Seok; Ou, Sai-Hong; Ahn, Myung-Ju; Park, Keunchil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-791</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR.  However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors.  Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear.  Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line.  Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clin. case.  The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiol. prevent the emergence of cells that are still dependent on EGFR signaling.  This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs.  Mol Cancer Ther; 11(3); 784-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhUxzW64OFLVg90H21EOLACvtfcHk0liGdwtr5QQlsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D&md5=3cd09bb1dd73f8045b93b054c79480d3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0750%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DAbolhoda%26aufirst%3DA.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DPark%26aufirst%3DK.%26atitle%3DThe%2520EGFR%2520T790M%2520mutation%2520in%2520acquired%2520resistance%2520to%2520an%2520irreversible%2520second-generation%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D784%26epage%3D791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonesaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwiatkowski, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2346</span><span class="NLM_x">–</span> <span class="NLM_lpage">2356</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=2346-2356&author=D.+Ercanauthor=K.+Zejnullahuauthor=K.+Yonesakaauthor=Y.+Xiaoauthor=M.+Capellettiauthor=A.+Rogersauthor=E.+Lifshitsauthor=A.+Brownauthor=C.+Leeauthor=J.+G.+Christensenauthor=D.+J.+Kwiatkowskiauthor=J.+A.+Engelmanauthor=P.+A.+J%C3%A4nne&title=Amplification+of+EGFR+T790M+causes+resistance+to+an+irreversible+EGFR+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DYonesaka%26aufirst%3DK.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DRogers%26aufirst%3DA.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DAmplification%2520of%2520EGFR%2520T790M%2520causes%2520resistance%2520to%2520an%2520irreversible%2520EGFR%2520inhibitor%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D2346%26epage%3D2356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">952</span><span class="NLM_x">–</span> <span class="NLM_lpage">962</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1158%2F1535-7163.MCT-11-0679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=22319204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2nurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=952-962&author=Y.+Panauthor=Y.+Xuauthor=S.+Fengauthor=S.+Luoauthor=R.+Zhengauthor=J.+Yangauthor=L.+Wangauthor=L.+Zhongauthor=H.+Y.+Yangauthor=B.+L.+Wangauthor=Y.+Yuauthor=J.+Liuauthor=Z.+Caoauthor=X.+Wangauthor=P.+Jiauthor=Z.+Wangauthor=X.+Chenauthor=S.+Zhangauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=SKLB1206%2C+a+novel+orally+available+multikinase+inhibitor+targeting+EGFR+activating+and+T790M+mutants%2C+ErbB2%2C+ErbB4%2C+and+VEGFR2%2C+displays+potent+antitumor+activity+both+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo</span></div><div class="casAuthors">Pan, Youli; Xu, Yong; Feng, Shan; Luo, Shidong; Zheng, Renlin; Yang, Jiao; Wang, Lijiao; Zhong, Lei; Yang, Han-Yu; Wang, Bing-Lin; Yu, Yang; Liu, Jingjing; Cao, Zhixing; Wang, Xiaoyan; Ji, Pan; Wang, Zerong; Chen, Xin; Zhang, Shuang; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">952-962</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-epidermal growth factor receptor (EGFR) treatment has been successfully applied in clin. cancer therapy.  However, the clin. efficacy of first-generation reversible EGFR inhibitors, such as gefitinib and erlotinib, is limited by the development of drug-resistant mutations, including the gatekeeper T790M mutation and upregulation of alternative signaling pathways.  Second-generation irreversible EGFR inhibitors that were designed to overcome the drug resistance due to the T790M mutation have thus far had limited success.  Here, we report a novel reversible EGFR inhibitor, SKLB1206, which has potent activity against EGFR with gefitinib-sensitive and -resistant (T790M) mutations.  In addn., SKLB1206 has also considerable inhibition potency against some other related oncokinases, including ErbB2, ErbB4, and VEGF receptor 2 (VEGFR2).  SKLB1206 exhibited highly antiproliferative activity against a range of EGFR-mutant cell lines, including gefitinib-sensitive and -resistant cell lines, and EGFR or ErbB2-overexpressing cell lines.  SKLB1206 also showed a potent antiangiogenesis effect in vitro, in a zebrafish embryonic angiogenesis assay, and in an alginate-encapsulate tumor cell assay.  In vivo, oral administration of SKLB1206 showed complete tumor regression in gefitinib-sensitive HCC827 and PC-9 xenograft models and showed a considerable antitumor effect on the gefitinib-resistant H1975 model as well as other EGFR/ErbB2-overexpressing or -dependent tumor models including A431, LoVo, and N87 established in athymic mice.  SKLB1206 also showed a very good oral bioavailability (50.1%).  Collectively, these preclin. evaluations may support clin. development of SKLB1206 for cancers with EGFR-activating/resistance mutations or EGFR/ErbB2 overexpressed.  Mol Cancer Ther; 11(4); 952-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohH2DvdBSqXrVg90H21EOLACvtfcHk0liiD76WLUH3hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2nurw%253D&md5=a920e9291f2fd615abb65de95f9a192a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0679%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DSKLB1206%252C%2520a%2520novel%2520orally%2520available%2520multikinase%2520inhibitor%2520targeting%2520EGFR%2520activating%2520and%2520T790M%2520mutants%252C%2520ErbB2%252C%2520ErbB4%252C%2520and%2520VEGFR2%252C%2520displays%2520potent%2520antitumor%2520activity%2520both%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D952%26epage%3D962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Antonello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarozzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morroni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrelia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, C.</span><span> </span><span class="NLM_article-title">Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6642</span><span class="NLM_x">–</span> <span class="NLM_lpage">6645</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0608762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6642-6645&author=A.+Antonelloauthor=A.+Tarozziauthor=F.+Morroniauthor=A.+Cavalliauthor=M.+Rosiniauthor=P.+Hreliaauthor=M.+L.+Bolognesiauthor=C.+Melchiorre&title=Multitarget-directed+drug+design+strategy%3A+a+novel+molecule+designed+to+block+epidermal+growth+factor+receptor+%28EGFR%29+and+to+exert+proapoptotic+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0608762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608762%26sid%3Dliteratum%253Aachs%26aulast%3DAntonello%26aufirst%3DA.%26aulast%3DTarozzi%26aufirst%3DA.%26aulast%3DMorroni%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DHrelia%26aufirst%3DP.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMultitarget-directed%2520drug%2520design%2520strategy%253A%2520a%2520novel%2520molecule%2520designed%2520to%2520block%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520to%2520exert%2520proapoptotic%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6642%26epage%3D6645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Wu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span> </span><span class="NLM_article-title">Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7316</span><span class="NLM_x">–</span> <span class="NLM_lpage">7326</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100607r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7316-7326&author=C.+H.+Wuauthor=M.+S.+Coumarauthor=C.+Y.+Chuauthor=W.+H.+Linauthor=Y.+R.+Chenauthor=C.+T.+Chenauthor=H.+Y.+Shiaoauthor=S.+Rafiauthor=S.+Y.+Wangauthor=H.+Hsuauthor=C.+H.+Chenauthor=C.+Y.+Changauthor=T.+Y.+Changauthor=T.+W.+Lienauthor=M.+Y.+Fangauthor=K.+C.+Yehauthor=C.+P.+Chenauthor=T.+K.+Yehauthor=S.+H.+Hsiehauthor=J.+T.+Hsuauthor=C.+C.+Liaoauthor=Y.+S.+Chaoauthor=H.+P.+Hsieh&title=Design+and+synthesis+of+tetrahydropyridothieno%5B2%2C3-d%5Dpyrimidine+scaffold+based+epidermal+growth+factor+receptor+%28EGFR%29+kinase+inhibitors%3A+the+role+of+side+chain+chirality+and+Michael+acceptor+group+for+maximal+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm100607r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100607r%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BR.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DShiao%26aufirst%3DH.%2BY.%26aulast%3DRafi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BY.%26aulast%3DHsu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DChang%26aufirst%3DT.%2BY.%26aulast%3DLien%26aufirst%3DT.%2BW.%26aulast%3DFang%26aufirst%3DM.%2BY.%26aulast%3DYeh%26aufirst%3DK.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DHsieh%26aufirst%3DS.%2BH.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DLiao%26aufirst%3DC.%2BC.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tetrahydropyridothieno%255B2%252C3-d%255Dpyrimidine%2520scaffold%2520based%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520kinase%2520inhibitors%253A%2520the%2520role%2520of%2520side%2520chain%2520chirality%2520and%2520Michael%2520acceptor%2520group%2520for%2520maximal%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7316%26epage%3D7326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oorui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8030</span><span class="NLM_x">–</span> <span class="NLM_lpage">8050</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2008634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8030-8050&author=T.+Ishikawaauthor=M.+Setoauthor=H.+Bannoauthor=Y.+Kawakitaauthor=M.+Ooruiauthor=T.+Taniguchiauthor=Y.+Ohtaauthor=T.+Tamuraauthor=A.+Nakayamaauthor=H.+Mikiauthor=H.+Kamiguchiauthor=T.+Tanakaauthor=N.+Habukaauthor=S.+Sogabeauthor=J.+Yanoauthor=K.+Aertgeertsauthor=K.+Kamiyama&title=Design+and+synthesis+of+novel+human+epidermal+growth+factor+receptor+2+%28HER2%29%2Fepidermal+growth+factor+receptor+%28EGFR%29+dual+inhibitors+bearing+a+pyrrolo%5B3%2C2-d%5Dpyrimidine+scaffold"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold</span></div><div class="casAuthors">Ishikawa, Tomoyasu; Seto, Masaki; Banno, Hiroshi; Kawakita, Youichi; Oorui, Mami; Taniguchi, Takahiko; Ohta, Yoshikazu; Tamura, Toshiya; Nakayama, Akiko; Miki, Hiroshi; Kamiguchi, Hidenori; Tanaka, Toshimasa; Habuka, Noriyuki; Sogabe, Satoshi; Yano, Jason; Aertgeerts, Kathleen; Kamiyama, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8030-8050</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer.  To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivs., e.g. I, capable of fitting into the receptors' ATP binding site.  Among the prepd. compds., I showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity.  The X-ray cocrystal structures of I with both HER2 and EGFR demonstrated that I interacts with the expected residues in their resp. ATP pockets.  Furthermore, reflecting its good oral bioavailability, I exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models.  On the basis of these findings, we report I (TAK-285) as a promising candidate for clin. development as a novel HER2/EGFR dual kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9QtqAj6idYrVg90H21EOLACvtfcHk0lgXI9cPazp7mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M&md5=ce030ac133a1c0ff7cb78b269ff85987</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm2008634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2008634%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DBanno%26aufirst%3DH.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DOorui%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DKamiyama%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252Fepidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520dual%2520inhibitors%2520bearing%2520a%2520pyrrolo%255B3%252C2-d%255Dpyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8030%26epage%3D8050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Jones, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glen, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span> </span><span class="NLM_article-title">Development and validation of a genetic algorithm for flexible docking</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1006%2Fjmbi.1996.0897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=9126849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1997&pages=727-748&author=G.+Jonesauthor=P.+Willettauthor=R.+C.+Glenauthor=A.+R.+Leachauthor=R.+Taylor&title=Development+and+validation+of+a+genetic+algorithm+for+flexible+docking"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a genetic algorithm for flexible docking</span></div><div class="casAuthors">Jones, Gareth; Willett, Peter; Glen, Robert C.; Leach, Andrew R.; Taylor, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">727-748</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Prediction of small mol. binding modes to macromols. of known three-dimensional structure is a problem of paramount importance in rational drug design (the "docking" problem).  We report the development and validation of the program GOLD (Genetic Optimization for Ligand Docking).  GOLD is an automated ligand docking program that uses a genetic algorithm to explore the full range of ligand conformational flexibility with partial flexibility of the protein and satisfies the fundamental requirement that the ligand must displace loosely bound water on binding.  Numerous enhancements and modifications have been applied to the original technique resulting in a substantial increase in the reliability and the applicability of the algorithm.  The advanced algorithm has been tested on a dataset of 100 complexes extd. from the Brookhaven Protein Data Bank.  When used to dock the ligand back into the binding site, GOLD achieved a 71% success rate in identifying the exptl. binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP3I60Rl2uorVg90H21EOLACvtfcHk0lgXI9cPazp7mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D&md5=476a2b1d8f80f3ba418052fe29d735ca</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1996.0897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1996.0897%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26aulast%3DWillett%26aufirst%3DP.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520genetic%2520algorithm%2520for%2520flexible%2520docking%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1997%26volume%3D267%26spage%3D727%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm301365e&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm301365e&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm301365e&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lgXI9cPazp7mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU','PDB','2JIU'); return false;">PDB: 2JIU</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301365e&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-23%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm301365e%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301365e" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993162780b3c58","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
